Login
Create Account
POSTER SESSION - Wednesday
Wednesday, 10 June 2026 (10:30 - 20:00)
Main Category
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
BIOMARKERS IN TISSUE AND BLOOD
CANCER CELL BIOLOGY
CANCER GENOMICS
CARCINOGENESIS
DRUG RESISTANCE
EPIGENETICS
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
IMMUNOTHERAPY
MOLECULAR AND GENETIC EPIDEMIOLOGY
PREVENTION AND EARLY DETECTION
RADIOBIOLOGY / RADIATION ONCOLOGY
SIGNALING PATHWAYS
TRANSLATIONAL RESEARCH
TUMOUR BIOLOGY
TUMOUR EVOLUTION AND HETEROGENEITY
TUMOUR IMMUNOLOGY
Session
Presenter & Country
Abstract No
Poster No
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
L1 Activity Shapes Genomic Instability in Bladder Cancer
Ivana Osredek
Germany
EACR26-0083
P-001
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Network-based modelling of tumour transcriptomes predicts immunotherapy response in HER2 negative breast cancer beyond conventional biomarkers
Caterina AM La Porta
Italy
EACR26-0125
P-002
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Descriptive analysis identifies cancer patient´s characteristics from the Basque population
Joseba Gabilondo-Rikondo
Spain
EACR26-0183
P-003
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Deep learning-based differential diagnosis of ovarian tumor using FDG PET/CT imaging
jieun jeong
South Korea
EACR26-0207
P-004
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Longitudinal multiomic features of host fecal miRNAs and the gut microbiome reveal distinct recovery dynamics in post-operative colorectal cancer
Nazim Arda Keles
Turkey
EACR26-0243
P-005
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Simulator of cancer-cell evolution for patient-specific therapy planning in cancer genome medicine
Mamoru Kato
Japan
EACR26-0253
P-006
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Analysis of data concordance across oncology patient-reported outcome measures (PROMs)
Thomas Moll
Switzerland
EACR26-0479
P-007
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Topographical archetypes of somatic mutagenesis in cancer
Doga C. Gulhan
United States
EACR26-0671
P-008
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Spatially informed tumor subclones identification in HER2-positive breast cancer reveals treatment-resistant populations
Lucie Cervenkova
Belgium
EACR26-0683
P-009
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
SPOT: New tool for exploratory phenotype analysis of organoids
Adam Norton-Steele
United Kingdom
EACR26-0751
P-010
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Sex-specific intratumoral microbiome signatures associated with treatment response in colorectal cancer
Claudia Machicado
Peru
EACR26-0773
P-011
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
How Well Do Pathology Foundation Models Perform on IHC Data? A Multi-Stain Study in Breast Cancer
Marcel Fischer
Switzerland
EACR26-0781
P-012
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Patient Stratification in iCCA Through Network Propagation of Somatic Mutations
Anastasiia Korosteleva
Ireland
EACR26-0855
P-013
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
EmbryoRadar – a machine learning model to uncover the impact of early embryonic transcriptional reawakening in cancer
Tongtong Wang
Australia
EACR26-0895
P-014
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Distinct Tex-like and Tpex-like transcriptional programs associate with subtype-specific prognosis in breast cancer
Otilia Menyhart
Hungary
EACR26-0903
P-015
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Comparative efficacy of HER2-targeted therapies in previously treated HER2-positive gastric cancer: a network meta-analysis
Otilia Menyhart
Hungary
EACR26-0917
P-016
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
CIDER: A Scalable, On-Premise LLM Framework for Automated Data Extraction in Clinical Cancer Research
Máté Posta
Hungary
EACR26-0931
P-017
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Standardized Analysis of Nationwide Incidence Data: Comparison of the Age Distribution of Tumor Types Between 2020 and 2024
Zsolt Nagy
Hungary
EACR26-0935
P-018
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Spatial Transcriptomics Reveals Clinically Relevant Microenvironmental Subtypes in HR+ HER2- Breast Cancer of No Special Type
Bengisu Karakose
Belgium
EACR26-0941
P-019
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
HCS‑3DX: An integrated platform for AI‑driven 3D high‑content screening in cancer research
Ákos Diósdi
Hungary
EACR26-0973
P-020
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Genome-Wide Analysis Reveals Increased LINE-1 Retrotransposition in Colorectal Cancer
Dániel Vörösvácki
Hungary
EACR26-0975
P-021
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Gene pathways related to neuronal differentiation are possibly involved in sustaining MiROvaR performance
Maria Pia Scarfone
Italy
EACR26-1085
P-022
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
NANO-SCOPE: Read-level tumor detection from cfDNA methylomes by Nanopore sequencing
Danial Tabbakh
Luxembourg
EACR26-1111
P-023
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
MET-CAV1 Fusion Transcripts and Their Impact on Fusion Partner Expression in Cancer
Yasemin Öztemur Islakoğlu
Turkey
EACR26-1151
P-024
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Proliferative and quiescent niches co-evolve in breast cancer
Maria Secrier
United Kingdom
EACR26-1253
P-027
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
HER2 Receptor Discordance in Metastatic Breast Cancer: Development and External Validation of a Predictive Model
Diego Arriaga-Izabal
Mexico
EACR26-1273
P-028
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Identification of a Robust 49-Gene Prognostic Signature for Triple-Negative Breast Cancer using Feature Selection in the SCAN-B Cohort
Lucía Martínez-Rodríguez
Spain
EACR26-1353
P-029
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Replication stress and stromal signalling define clinically actionable triple-negative breast cancer subtypes
Javier Rodriguez
United Kingdom
EACR26-1401
P-030
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Structural radicality of T-cell exposed mutations predicts neoepitope immunogenicity
Gergő Balogh
Hungary
EACR26-1517
P-031
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Bioinformatic Identification of Biomarkers Predicting Sensitivity to Pharmacological ELP3 Inhibition
Ingrid Matchoua Tchoboue
Belgium
EACR26-1531
P-032
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Spatial transcriptomics and spatial proteomics from the same tissue section enable integrated spatial multi-omics analysis
Sergi Beneyto-Calabuig
Switzerland
EACR26-1543
P-033
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Identifying Tractable Stromal Vulnerabilities in Pancreatic Cancer-Associated Fibroblasts to Restore Anti-Tumour Immunity
Constance Maurer
United Kingdom
EACR26-1621
P-034
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Machine learning–based Treg signature predicts clinical outcomes and immune landscape in ovarian cancer
Hyunmin Woo
South Korea
EACR26-1647
P-036
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Integrated spatial triple-omics combining COMET hyperplex and spatial lipidomics to profile melanoma cell subtypes in situ
Jonathan Sai-Hong Chui
Belgium
EACR26-1667
P-037
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
In silico Drug Repurposing Candidates Targeting Wild-Type and Mutant ABL1, EGFR, and BRAF
Claudia Machicado
Peru
EACR26-1735
P-039
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Virtual CRISPR Drug-Modifier and Combination Screens Enable Scalable, Context-Specific Target Discovery and Ranking
Csilla Hegedus
Hungary
EACR26-1793
P-040
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
State-Specific Reprogramming of the GCH1-EMT Axis: A Multi-Omics Pan-Cancer Analysis Comparing Normal and Tumor Interactomes
Chih-Hsun Wu
Taiwan
EACR26-1805
P-041
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Identifying Novel Immune Biomarker Candidates for Axillary Metastasis in Breast Cancer through Machine Learning and Network Modeling
Alba Fischer-Carles
Spain
EACR26-1875
P-042
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Top Genes Are Not a Single Answer: Auditing Feature-Selection Leakage and Biomarker Instability in XGBoost Transcriptomic Models
Qirui Tian
United Kingdom
EACR26-1927
P-043
BIOMARKERS IN TISSUE AND BLOOD
BRCA2 expression as a predictive biomarker of response to DNA-damaging cytotoxics in neuroblastoma
Zhi Xiong Chen
Singapore
EACR26-0069
P-045
BIOMARKERS IN TISSUE AND BLOOD
Contactin-1–Notch-2 Signalling as a Prognostic Axis in Clinical Breast Cancer
Amber X. Li
United Kingdom
EACR26-0073
P-046
BIOMARKERS IN TISSUE AND BLOOD
Early and accurate detection of ovarian cancer by profiling cell-free mitochondrial DNA fragmentomics in multi-ethnic population
Yang Liu
China
EACR26-0101
P-047
BIOMARKERS IN TISSUE AND BLOOD
Putative Imprinting Control Regions with Aberrant Blood-Based DNA Methylation Are Associated with Hepatocellular Carcinoma Risk
Annie DiFrank
United States
EACR26-0187
P-048
BIOMARKERS IN TISSUE AND BLOOD
Genomic Instability Score in Diverse Tumor Types Using Illumina TruSight Oncology 500 HRD
Moonsik Kim
South Korea
EACR26-0241
P-050
BIOMARKERS IN TISSUE AND BLOOD
Determining functional homologous recombination capacity in de novo metastatic prostate cancer
Ezgi Karagöz
Finland
EACR26-0329
P-051
BIOMARKERS IN TISSUE AND BLOOD
Spatial transcriptomics reveals NGFR as a prognostic biomarker and translational target in high tumor budding triple-negative breast cancer
Rungdawan Wongsamart
Thailand
EACR26-0335
P-052
BIOMARKERS IN TISSUE AND BLOOD
ATR-IR Spectroscopy as a non-invasive tool for early detection and personalized treatment of pancreatic cancer
Anne Wedemann
Germany
EACR26-0445
P-053
BIOMARKERS IN TISSUE AND BLOOD
A Cost-effective Scalable Workflow for Clinical Blood Monitoring using GEM-X Flex v2 (Apex) Single-Cell Transcriptomic Profiling
Tingsheng Drennon
United States
EACR26-0477
P-055
BIOMARKERS IN TISSUE AND BLOOD
Promising serum metabolite markers for the early detection of colorectal cancer
Yanqun Liu
Singapore
EACR26-0489
P-056
BIOMARKERS IN TISSUE AND BLOOD
Tracking FGFR3 and PIK3CA Mutations in Bladder Cancer via Plasma and Urine ddPCR
Eleni Thanou
Greece
EACR26-0509
P-057
BIOMARKERS IN TISSUE AND BLOOD
MOLECULAR CHARACTERISTICS AND IMMUNOPHENOTYPING OF TUMOR INFILTRATING LYMPHOCYTES (TILs) OF HIGH GENOMIC SCARRING SCORE (GSS) METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC)
Pantelis Konstantoulakis
Greece
EACR26-0571
P-058
BIOMARKERS IN TISSUE AND BLOOD
Utilization of flow cytometry for the characterization of epithelial, mesenchymal and embryonic properties of circulating tumor cells
Tamas Richard Linkner
Hungary
EACR26-0641
P-059
BIOMARKERS IN TISSUE AND BLOOD
YB-1 is involved in drug resistance and poor patient prognosis in thoracic cancers
Laura Schnell
Austria
EACR26-0659
P-060
BIOMARKERS IN TISSUE AND BLOOD
Point-of care detection of PIK3CA mutations for breast cancer therapy selection
Manuela Hofner
Austria
EACR26-0717
P-062
BIOMARKERS IN TISSUE AND BLOOD
Evaluation of a QIAcuityDx multiplexed digital PCR system for the detection and quantification of IDH1 and IDH2 mutations
Alyx FAUREL
France
EACR26-0723
P-063
BIOMARKERS IN TISSUE AND BLOOD
Assessing the Prognostic Role of Nuclear and Membrane Progesterone Receptors Through Gene Expression Analysis in Head and Neck Squamous Cell Carcinoma
Petar Ozretic
Croatia
EACR26-0739
P-064
BIOMARKERS IN TISSUE AND BLOOD
Circulating DNA methylation patterns identify patients at high risk of stage II melanoma recurrence
Wei Yen Chan
Australia
EACR26-0891
P-065
BIOMARKERS IN TISSUE AND BLOOD
Biopsy-Based Proteomics Identifies Treatment-Specific Biological Pathways Underlying Response in Advanced Hepatocellular Carcinoma
Frederic Saltel
France
EACR26-0899
P-066
BIOMARKERS IN TISSUE AND BLOOD
Prognostic value of ITGA6 mRNA isoforms and association with surface CD49f expression in pediatric B-cell acute lymphoblastic leukemia
Anna Hunyadi
Hungary
EACR26-0913
P-067
BIOMARKERS IN TISSUE AND BLOOD
Neuron-Tumour crosstalk: Synaptic Monoamine Receptor Profiling as a Prognostic and Therapeutic Roadmap for Glioblastoma
Claudia Abbruzzese
Italy
EACR26-0993
P-068
BIOMARKERS IN TISSUE AND BLOOD
Digital morphometry and cluster analysis identifies HGSOC patients with different prognosis
Eros Azzalini
Italy
EACR26-0995
P-069
BIOMARKERS IN TISSUE AND BLOOD
MiR-22 targets the G2/M checkpoint inhibitor WEE1 and represents a biomarker of TACE response in hepatocellular carcinoma
Clara Vianello
Italy
EACR26-1039
P-070
BIOMARKERS IN TISSUE AND BLOOD
Elevated Lipocalin 2 Expression Drives the Acquisition of Radioresistance in HNSCC: Clinical and In Vitro Evidence
Smriti Suri
India
EACR26-1133
P-071
BIOMARKERS IN TISSUE AND BLOOD
Gene expression–based molecular subtypes associated with prognosis in Colombian colorectal cancer
Wendy Montero-Ovalle
Colombia
EACR26-1231
P-072
BIOMARKERS IN TISSUE AND BLOOD
Developing a nanobiotechnology platform for circulating tumour cell detection and therapy-relevant phenotyping in breast cancer
Victoria Ie Ching Tan
Australia
EACR26-1239
P-073
BIOMARKERS IN TISSUE AND BLOOD
High-sensitivity T-cell receptor (TCR) repertoire profiling from plasma cell-free DNA for non-invasive immune monitoring
Paul Diehl
United States
EACR26-1243
P-074
BIOMARKERS IN TISSUE AND BLOOD
PCDH10 as an Independent Prognostic Biomarker and Functional Regulator in HER2-Positive Breast Cancer
Amber X Li
United Kingdom
EACR26-1347
P-075
BIOMARKERS IN TISSUE AND BLOOD
LCN2 as a Novel Urinary Biomarker for Early Detection and Prognosis of Bladder Cancer
Seo-Yeong Yoon
South Korea
EACR26-1381
P-077
BIOMARKERS IN TISSUE AND BLOOD
Integrating Tissue and Liquid Biopsies: Assessing NGS-Based Molecular Characterization and cfDNA Limitations in Gastroesophageal Adenocarcinoma
Matteo Curtarello
Italy
EACR26-1413
P-078
BIOMARKERS IN TISSUE AND BLOOD
Qualification of translational spatial biomarker panels to enable predictive tissue profiling in oncology drug development
David Bonnel
France
EACR26-1495
P-079
BIOMARKERS IN TISSUE AND BLOOD
Cytoblock-Based Immunocytochemistry Enables Multiparametric Characterization of Circulating Tumor Cells in Lung Cancer
Meryem AARAB
Morocco
EACR26-1497
P-080
BIOMARKERS IN TISSUE AND BLOOD
Ex vivo TruCulture/L blood culture tubes enable sensitive, longitudinal pharmacodynamic assessment of AZD1390 in patient PBMCs when tumour biopsies are not feasible
Athanasios Karapetsas
United Kingdom
EACR26-1515
P-081
BIOMARKERS IN TISSUE AND BLOOD
Soluble Endo180 shedding by MMP2 predicts lymph node micrometastasis and an unfavourable prognosis in breast cancer
Mercedes Rodriguez-Teja
Uruguay
EACR26-1547
P-082
BIOMARKERS IN TISSUE AND BLOOD
The role of circulating tumour cell clusters in prostate cancer metastasis
Yong-Jie Lu
United Kingdom
EACR26-1587
P-084
BIOMARKERS IN TISSUE AND BLOOD
Quantitative PTPRT Methylation Assessment in HNSCC and Its Association with Clinical Benefit from Immune Checkpoint Blockade
Eva Riveira-Muñoz
Spain
EACR26-1691
P-085
BIOMARKERS IN TISSUE AND BLOOD
A Whole Blood Functional Flow Cytometry Assay to Characterize Host Response and Heterogeneity to CAR-T Cell Immunotherapy
Laurine BODIN
France
EACR26-1741
P-086
BIOMARKERS IN TISSUE AND BLOOD
NALCN Promoter Methylation in Circulating Tumor Cells and paired plasma-cfDNA in Breast Cancer
Elina Lagopodi
Greece
EACR26-1745
P-087
BIOMARKERS IN TISSUE AND BLOOD
Integrated Single-Nuclei and Spatial Transcriptomics at Scale Uncovers Clinically Relevant Heterogeneity in Malignant Pleural Mesothelioma
Krisztian Homicsko
Switzerland
EACR26-1747
P-088
BIOMARKERS IN TISSUE AND BLOOD
Routine isolation and single-cell molecular profiling of circulating tumor cells to guide personalized cancer therapy
Alberto Gil-Jimenez
Netherlands
EACR26-1753
P-089
BIOMARKERS IN TISSUE AND BLOOD
Peripheral immune profiles differentiate early and late onset colorectal cancer and suggest potential blood-based biomarkers
María González
Spain
EACR26-1785
P-090
BIOMARKERS IN TISSUE AND BLOOD
Proteins and DNA of Plasma Exosomes in Colorectal cancer
alisa petkevich
Russia
EACR26-1889
P-092
BIOMARKERS IN TISSUE AND BLOOD
In-depth multi-platform plasma proteomics and machine learning identify potential biomarkers for lung adenocarcinoma
Noora Sissala
Sweden
EACR26-1891
P-093
BIOMARKERS IN TISSUE AND BLOOD
Integrating hematoxylin & eosin histology with multiplexed Imaging Mass Cytometry for spatial proteomic profiling of antibody-drug conjugate targeted biomarkers
Daniela Natale
Italy
EACR26-1925
P-094
CANCER CELL BIOLOGY
Dual Targeting of PKN2-Driven Mechanotransduction and Tumour Stroma to Overcome Resistance in Triple-Negative Breast Cancer
Siti Munira Abd Jalil
Malaysia
EACR26-0077
P-095
CANCER CELL BIOLOGY
Tumor Nitrogen Metabolism at the Cellular Level: Insights from N Isotope Ratios
Alessandra Eleonora Carioli
Switzerland
EACR26-0129
P-097
CANCER CELL BIOLOGY
Spatial membrane lipid remodeling differentiates epithelial lineage and state in human colon cancer
Gwendolyn Barceló-Coblijn
Spain
EACR26-0151
P-098
CANCER CELL BIOLOGY
NPM1-driven glucose metabolic remodeling: implications for prostate cancer progression and treatment
Akhil Shukla
Canada
EACR26-0219
P-100
CANCER CELL BIOLOGY
Clinical and prognostic significance of APOC3 (apolipoprotein-C3) in human colorectal cancer
Wang weichen
United Kingdom
EACR26-0223
P-101
CANCER CELL BIOLOGY
A Conserved Role for PKN2 in Epithelial Junction Stability and Suppression of Inflammation-Driven Colorectal Tumorigenesis
Ashley Campbell
United Kingdom
EACR26-0259
P-102
CANCER CELL BIOLOGY
Identifying and Targeting Survival Pathway Vulnerabilities in Chemotherapy-Induced Senescent Cancer Cells
Mohamad Rima
Lebanon
EACR26-0271
P-103
CANCER CELL BIOLOGY
WISP3 sensitizes pancreatic cancer to gemcitabine by inducing oxidative stress and mitochondrial dysfunction
Jihyun Shin
South Korea
EACR26-0299
P-104
CANCER CELL BIOLOGY
AXL-Driven TNFR1 Upregulation Connects EMT to Inflammatory Signaling in Melanoma
Mikolaj Kepa
Austria
EACR26-0325
P-105
CANCER CELL BIOLOGY
TCF7L2 mutations attenuate a Wnt-independent inflammatory vulnerability in colorectal cancer
Barbara Lupo
Italy
EACR26-0337
P-106
CANCER CELL BIOLOGY
Areca Nut Induces Fibroblast Senescence and Oral Precancer Progression through Activation of IL-6/JAK2/STAT3 Signaling
Yen-Yun Wang
Taiwan
EACR26-0345
P-107
CANCER CELL BIOLOGY
Function of sortilin in the cancer stem cell population in early- and late-stage non-small cell lung cancer
Andreea Andreev
France
EACR26-0355
P-108
CANCER CELL BIOLOGY
Investigation of the anti-cancer effects of the prenylated flavonoid dehydroglyasperin C in nasopharyngeal carcinoma cells
Hsin-Yu Ho
Taiwan
EACR26-0359
P-109
CANCER CELL BIOLOGY
Histone Acetyltransferase 1 (HAT1) regulation of Myc- A new therapeutic vulnerability
Kaval Reddy Prasasvi
India
EACR26-0373
P-110
CANCER CELL BIOLOGY
NONO Regulates EMT-Associated Metastatic Traits in Lung Cancer Cells and Modulates c-Myc Activity
Shirani Punniyamoorthy
India
EACR26-0389
P-111
CANCER CELL BIOLOGY
Regulatory mechanisms of serine biosynthesis and its catabolism in promoting glioblastoma growth
Hye Jin Yun
South Korea
EACR26-0429
P-113
CANCER CELL BIOLOGY
FGF/FGFR System in Medulloblastoma: New Approaches for Tumor Treatment.
Nicolas Tassone
Italy
EACR26-0437
P-114
CANCER CELL BIOLOGY
Transcriptional stress-response signatures and G0/G1 redistribution following vemurafenib treatment in primary histiocytic lesion–derived cells*
Agnieszka Śmieszek
Poland
EACR26-0453
P-115
CANCER CELL BIOLOGY
A Novel Oncogenic–Metabolic Axis as a Therapeutic Vulnerability in Multiple Myeloma Survival
Aqeelah Mohammad
United Kingdom
EACR26-0471
P-116
CANCER CELL BIOLOGY
VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytes
Gyorgy Hajnoczky
United States
EACR26-0481
P-117
CANCER CELL BIOLOGY
Waterpipe smoke activates protective autophagy in normal lung cells linking it to carcinogenic changes
Rania Zaarour
United Arab Emirates
EACR26-0511
P-119
CANCER CELL BIOLOGY
ET1/ETAR/NOX signaling enhances invadopodia formation, thereby promoting cell invasion in gallbladder cancer cells
Nelson Quilaqueo-Millaqueo
Chile
EACR26-0539
P-120
CANCER CELL BIOLOGY
Targeting HIF-1α-SHMT axis disrupts serine catabolism-mediated ferroptosis resistance in serine/glycine-limited glioblastoma
Hye Jin Yun
South Korea
EACR26-0567
P-121
CANCER CELL BIOLOGY
The role of hnRNP A1 in modeling cancer cell plasticity and invasive potential in relation to the expression of CD44 splice forms in esophageal squamous cell carcinoma
Renata Tabola
Poland
EACR26-0579
P-122
CANCER CELL BIOLOGY
Germline MUTYH variants in breast cancer: functional consequences and associated regulatory mechanisms
Yixiao Gan
Hong Kong, China
EACR26-0581
P-123
CANCER CELL BIOLOGY
HDAC6 knockout enhances vinorelbine sensitivity and alters stress granule maintenance in lung adenocarcinoma cells
Joanna Sobocinska
Switzerland
EACR26-0593
P-124
CANCER CELL BIOLOGY
Hypertranscription caused by P53 deficiency triggers nucleotide insufficiency that induces replication stress and genomic instability
Wisam Zaatra
Israel
EACR26-0603
P-125
CANCER CELL BIOLOGY
Cyclin Dependent Kinase 4 (CDK4) maintains cell cytoskeleton integrity and behavior in Triple Negative Breast Cancer (TNBC) cells
Kanishka Parashar
Switzerland
EACR26-0615
P-126
CANCER CELL BIOLOGY
Metabolic Modulation Potentiates Targeted Therapy Efficacy Across Distinct NSCLC Subtype
Viviana De Rosa
Italy
EACR26-0619
P-127
CANCER CELL BIOLOGY
The spliceosome is a selective therapeutic liability in RAS-driven senescent and cancer cells
Laura Bousset
United Kingdom
EACR26-0635
P-128
CANCER CELL BIOLOGY
miR-376c-3p as a Post-Transcriptional Regulator of TACSTD2 Oncogene
Irmak Gürcüoglu
Germany
EACR26-0647
P-129
CANCER CELL BIOLOGY
Cell cycle control through transcription: tumor suppressors (p53, RB, DREAM) counteracting oncogenic drivers (A-MYB, B-MYB, E2F, FOXM1)
Kurt Engeland
Germany
EACR26-0651
P-130
CANCER CELL BIOLOGY
MBOAT7-Driven “Lipid shield” and Trans-Sulfuration Bypass Define a “Metabolic Fortress” in STK11/ KRAS-Mutant Lung Adenocarcinoma
Massimo Moro
Italy
EACR26-0703
P-131
CANCER CELL BIOLOGY
Spatial and functional segregation of mitochondria during melanoma cell migration
Clara Gil
France
EACR26-0733
P-132
CANCER CELL BIOLOGY
Reversible EMT in lung cancer cells drives concordant exosomal microRNA remodelling
Keun Hur
South Korea
EACR26-0753
P-133
CANCER CELL BIOLOGY
IDH1 Mutation Creates Ferroptotic Vulnerability Through Redox Imbalance, Iron Dysregulation, and Lipid Remodeling in Glioma
Yigit Emre Altin
Turkey
EACR26-0771
P-134
CANCER CELL BIOLOGY
Mutant CHIP/STUB1 with Compromised E3 Ubiquitin Ligase Activity Dampens MAPK Signaling by Targeting Oncogenic BRAF(V600E)
JI-YUN LEE
South Korea
EACR26-0787
P-135
CANCER CELL BIOLOGY
Single-cell RNA sequencing reveals a heterogenous landscape of putative precancerous cell states in the subventricular zone of glioblastoma patients
Yiseul Kim
South Korea
EACR26-0789
P-136
CANCER CELL BIOLOGY
Enhancing immunogenic cell death to improve treatment outcomes to KRAS mutant specific inhibitors in lung adenocarcinoma
Elizabeth Lieschke
United Kingdom
EACR26-0801
P-137
CANCER CELL BIOLOGY
Oncofetal ROR1 Promotes Hepatocellular Carcinoma Advancement through Actin Cytoskeleton Remodeling and Cancer-Associated Fibroblast Recruitment
Yanshu Kong
Hong Kong, China
EACR26-0805
P-138
CANCER CELL BIOLOGY
Constitutive and Stress-Responsive SLC7A11 Programs Underlie Ferroptosis-Linked Cisplatin Resistance in Gastric Cancer
Jinkyung Choi
South Korea
EACR26-0811
P-139
CANCER CELL BIOLOGY
Senescence-Associated GLS1 Isoform Switching Rewires Glutamine Metabolism to Promote Cancer Cell Survival
Hyojin Lim
South Korea
EACR26-0829
P-140
CANCER CELL BIOLOGY
YWHAZ Overexpression Acts as a Molecular Link in the Transition of Bladder Cancer from NMIBC to MIBC
Jim Sheu
Taiwan
EACR26-0849
P-141
CANCER CELL BIOLOGY
PSRC1 promotes oncogenic dedifferentiation in TP53-mutated hepatocellular carcinoma
Jingyi Yuan
Hong Kong, China
EACR26-0851
P-142
CANCER CELL BIOLOGY
Unveiling the role of TET3-mediated NMUR2 expression in the progression of pancreatic cancer
Yuna Roh
South Korea
EACR26-0857
P-143
CANCER CELL BIOLOGY
Enhancing Radiosensitivity in Prostate Cancer Through Modulation of Androgen Receptor/miR -181a-5p /c-Met Axes
Peyda Korhan
Turkey
EACR26-0893
P-144
CANCER CELL BIOLOGY
Unraveling signaling pathways involved in epithelial-mesenchymal transition triggered by Neutrophil Extracellular Traps (NETs) in cancer cells
Tayyaba Mehmood
Italy
EACR26-0921
P-145
CANCER CELL BIOLOGY
Mesothelial-to-Mesenchymal Transition Contributes to Fibrotic Niche Formation in Colorectal Cancer Peritoneal Metastasis
Mahsa Mohammadi
United Kingdom
EACR26-0927
P-146
CANCER CELL BIOLOGY
HRASG12V-driven transcriptional reprogramming promotes R-loop accumulation and genomic instability at fragile sites
Reem Aldwaik
Israel
EACR26-0945
P-147
CANCER CELL BIOLOGY
Single cell cloning iPSCs with the Pala single cell sorter preserves colony stemness and cell viability for high-throughput cell line engineering workflows
Nico Dankbar
Germany
EACR26-0947
P-148
CANCER CELL BIOLOGY
SCAP dependency defines a targetable metabolic vulnerability in synovial sarcoma
Larissa Frasch
Germany
EACR26-0953
P-149
CANCER CELL BIOLOGY
ATG7 function promotes pancreatic cancer progression independently of autophagy
Clémence Larat
Iceland
EACR26-0977
P-150
CANCER CELL BIOLOGY
Investigating the Role of TRPM7 in Breast Cancer Progression and Metabolic Regulation
Marialaura Giannaccari
Italy
EACR26-0999
P-151
CANCER CELL BIOLOGY
Identifying novel mechanisms controlling cancer stem cells to target glioma growth
Rosie Moore
United Kingdom
EACR26-1051
P-152
CANCER CELL BIOLOGY
Charting intratumoral steroid metabolism in patient-derived endometrial cancer organoids
Merve Yildiz
Netherlands
EACR26-1109
P-153
CANCER CELL BIOLOGY
WDR66 influences stemness, resistance to therapy and immunomodulation in head and neck squamous cell carcinoma
Manuel Celis-Romero
Spain
EACR26-1117
P-154
CANCER CELL BIOLOGY
Calreticulin overexpression induces pro-tumoral features and molecular changes in dysplastic oral keratinocytes.
Nathalia Marques
Brazil
EACR26-1127
P-155
CANCER CELL BIOLOGY
MIF-Mediated Tumor Microenvironment Signaling in Glioblastoma Invasion and Vasculogenic Remodeling
Mirvat El-Sibai
Lebanon
EACR26-1169
P-156
CANCER CELL BIOLOGY
Tubulin beta 6 upregulation and paclitaxel resistance in ovarian cancer cells are linked to overexpression of the erythropoietin receptor
Martina Semelakova
Slovakia
EACR26-1171
P-157
CANCER CELL BIOLOGY
Modulation of tmCLIC1 Electrophysiological Activity to Enhance Metformin Response in Glioblastoma Cells
Sara Torabi
Italy
EACR26-1175
P-158
CANCER CELL BIOLOGY
Molecular Mechanisms of MyomiR-133b–Mediated Tumor Suppression in HCT116 Colorectal Cancer Cells
Tímea Kurdiová
Slovakia
EACR26-1177
P-159
CANCER CELL BIOLOGY
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability
Mariantonietta D'Ambrosio
United Kingdom
EACR26-1191
P-160
CANCER CELL BIOLOGY
Elucidating the role of p53 loss and/or PIK3CAH1047R overexpression in replication stress and genomic instability
Omer Setty
Israel
EACR26-1211
P-161
CANCER CELL BIOLOGY
TSR3 ribosome maturation factor associates with aggressive cell states and poor outcomes in neuroblastoma
Adna Goralija
Czech Republic
EACR26-1217
P-163
CANCER CELL BIOLOGY
Pdcd4–Rictor Interaction Suppresses PFKFB3 to inhibit Tumorigenesis
Hsin-Sheng Yang
United States
EACR26-1223
P-164
CANCER CELL BIOLOGY
Therapy-induced secretomic Galectin-1 orchestrates EMT and ferroptosis resistance in Triple Negative Breast Cancer
Shagufa Aram Shaikh
India
EACR26-1345
P-166
CANCER CELL BIOLOGY
The absence of MEK5 & the effects of TanIIA on proliferation
Irem Nur Cetin
Turkey
EACR26-1351
P-167
CANCER CELL BIOLOGY
Tocotrienol Rich Fraction Modulates Leptin Reduced Chemotherapy Response in Colorectal Cancer and Adipocyte Derived Signals.
Rilwan Abdullahi
Malaysia
EACR26-1379
P-168
CANCER CELL BIOLOGY
Dysregulation of UFMylation pathway is linked to cancer stem cells and correlates with unfavorable prognosis in head and neck cancer
Kristina Vukovic Derfi
Croatia
EACR26-1385
P-169
CANCER CELL BIOLOGY
The role of NINJ1 in cancer cell death
Borna Bacinger
Slovenia
EACR26-1387
P-170
CANCER CELL BIOLOGY
Treatment resistance alters responses to hypoxia in prostate cancer cells.
Alvar Lauri Vilho Saarinen
Finland
EACR26-1397
P-171
CANCER CELL BIOLOGY
Spatial proteomics reveals tryptophan metabolism driving ovarian cancer survival
Teng Teng Xu
Germany
EACR26-1415
P-172
CANCER CELL BIOLOGY
Modulation of the Serine Synthesis Pathway by cisplatin and curcumin is highly dependent on cell culture media composition
Sara Zvonar
Croatia
EACR26-1427
P-173
CANCER CELL BIOLOGY
Targeting Cholesterol Metabolism to Modulate Mitochondrial Morphology in Prostate Cancer
Aino Siltari
Denmark
EACR26-1439
P-174
CANCER CELL BIOLOGY
Loss of p27kip1 drives mTORC1-dependent senescence escape after CDK4/6 inhibition in hormone receptor-positive breast cancer
Nicole Crestan
Italy
EACR26-1441
P-175
CANCER CELL BIOLOGY
Revealing CDK6 dependency through highly selective pharmacological inhibition or precision targeting of CDK6: A new therapeutic avenue for AML
Nyree Crawford
United Kingdom
EACR26-1467
P-176
CANCER CELL BIOLOGY
Investigating the Role of Fatty Acid Synthase Inhibition on Immune Checkpoint Expression in Prostate Cancer
Hugo Turnbull-Hall
United Kingdom
EACR26-1477
P-177
CANCER CELL BIOLOGY
Interaction of Erastin, a ferroptosis-inducing agent, with Etoposide or RG7388 in Neuroblastoma Cells.
Selda Kabadere
Turkey
EACR26-1483
P-178
CANCER CELL BIOLOGY
CD44 as a novel potential target to reduce cancer stemness properties and increase sensitivity in Glioblastoma models.
Valeria Di Benedetto
Italy
EACR26-1509
P-180
CANCER CELL BIOLOGY
Investigating the influence of tumor cell plasticity on breast cancer metastasis
Eva Chrenková
Austria
EACR26-1513
P-181
CANCER CELL BIOLOGY
Molecular-level understanding about gemcitabin resistance in cholangiocarcinoma: 2D in vitro models of cholangiocarcinoma (CCA)
Aslı Kutlu
Turkey
EACR26-1521
P-182
CANCER CELL BIOLOGY
Proton-Imposed Lipid Intake (PILI): How Extracellular Acidosis Redirects Cancer Cell Metabolism
Sébastien Ibanez
Belgium
EACR26-1539
P-183
CANCER CELL BIOLOGY
Epithelial–Mesenchymal Plasticity underlies adaptive chemoresistance in Esophageal Adenocarcinoma
Laurie CLAUZON
Italy
EACR26-1565
P-184
CANCER CELL BIOLOGY
Decoding Tumor Cell Invasive Switch
Maria John
Norway
EACR26-1571
P-185
CANCER CELL BIOLOGY
SNAI2 as a Key Regulator of EWS-WT1 (+KTS) Oncogenic Function in Desmoplastic Small Round Cell Tumour
Laura Lobo Selma
Spain
EACR26-1585
P-186
CANCER CELL BIOLOGY
Novel cumate-inducible models of MYC-driven neuroblastoma enable mitochondrial synthetic lethality screens without inducer-associated toxicity
Adela Kubistova
Czech Republic
EACR26-1597
P-187
CANCER CELL BIOLOGY
Carcinogen exposed differentiated human primary airway cultures recapitulate early lung squamous carcinogenesis and reveals therapeutically targetable preinvasive cell states
Wenrui Guo
United Kingdom
EACR26-1613
P-188
CANCER CELL BIOLOGY
Nucleotide Imbalance and Ribonucleotide Reductase Isoforms Regulate Replication Stress–Induced Differentiation in Acute Myeloid Leukemia
Alojzija Brcic
Croatia
EACR26-1631
P-189
CANCER CELL BIOLOGY
Unlocking the mitochondrial death pathway in prostate cancer for therapeutic benefit
Laura Martínez-Escardó
United Kingdom
EACR26-1639
P-190
CANCER CELL BIOLOGY
Nucleotide Imbalance and Redox Control of Hydroxyurea-Induced Differentiation in AML
Klara Bardac
Croatia
EACR26-1657
P-191
CANCER CELL BIOLOGY
CDH11 sustains metastasis-initiating cells and metastatic dissemination and represents a potential blood-based biomarker
Fabio Murianni
Italy
EACR26-1725
P-193
CANCER CELL BIOLOGY
Mitochondrial ROS inhibition prevents doxorubicin-induced breast cancer cell migration and invasion
Pierre Sonveaux
Belgium
EACR26-1729
P-194
CANCER CELL BIOLOGY
Feeding on fat: metabolic adaptation in diffuse gastric cancer metastasis
Ana Maria Pedro
Portugal
EACR26-1771
P-195
CANCER CELL BIOLOGY
Dysregulation of Hepatic cAMP/PKA/CREB1 Signaling in Cancer Cachexia
Alessia Meschi
Italy
EACR26-1801
P-197
CANCER CELL BIOLOGY
EGFRvIII-Engineered patient-derived glioblastoma cells as a Versatile Platform for Modeling EGFRvIII-Driven Tumors
Beatrice Gallo
Italy
EACR26-1815
P-198
CANCER CELL BIOLOGY
High-plasticity cell state in intestinal tumor stem cells is boosted by modulation of Wnt/b-catenin signaling
Pauliina Kallio
Finland
EACR26-1829
P-199
CANCER CELL BIOLOGY
Impaired licensing of DNA replication as a factor in synthetic lethal interactions in colorectal cancer
Argyro Kalogeropoulou
Greece
EACR26-1841
P-200
CANCER CELL BIOLOGY
NUAK1 promotes the pentose phosphate pathway via hnRNPK-G6PD and favors oxaliplatin chemoresistance.
Luis Espinoza-Francine
Chile
EACR26-1843
P-201
CANCER CELL BIOLOGY
The role of dimensionality and extracellular matrix formation in 3D bioprinted breast cancer models
Dorottya Moldvai
Hungary
EACR26-1857
P-202
CANCER CELL BIOLOGY
TMED9 promotes EMT-mediated progression, migration, and proliferation in glioblastoma
Şeyma Punar
Turkey
EACR26-1861
P-203
CANCER CELL BIOLOGY
Very Long Chain Fatty Acid Synthesis is a Metabolic Dependency and Therapeutic Target in NRAS Mutant Myeloid Leukemia
Rebecca Gelfer
United States
EACR26-1869
P-204
CANCER CELL BIOLOGY
Pancreatic cancer cell adaptation to mechanical compressive stress reveals a targetable vulnerability and synergistic effect of SRC and PI3K inhibitors.
Julie Guillermet-Guibert
France
EACR26-1915
P-205
CANCER CELL BIOLOGY
Spatial proteomic profiling of metabolic and cell signaling heterogeneity in Breast Cancer tumor microenvironment using Imaging Mass Cytometry
Daniela Natale
Italy
EACR26-1921
P-206
CANCER CELL BIOLOGY
Molecular and clinical implications of WRN (Werner Syndrome Protein) and WRN interactive protein in the development and Progression of breast cancer
FARID ASKR
United Kingdom
EACR26-2005
P-207
CANCER GENOMICS
Intrahepatic reporter assay reveals leaky somatic blockade of L1 retrotransposition in mice
Lajos Mátés
Hungary
EACR26-0215
P-208
CANCER GENOMICS
Single-Cell Resolution of Malignant Reprogramming and Immune Dysregulation Identifies Prognostic Signatures in Oral Submucous Fibrosis-Associated Oral Cancer
Arunima Acharya
India
EACR26-0233
P-209
CANCER GENOMICS
An RNA-targeted strategy to enhance PARP inhibitor sensitivity in triple-negative breast cancer
Xue Lu
Australia
EACR26-0407
P-210
CANCER GENOMICS
Genomic instability and complex structural events drive the evolution of malignant pleural mesothelioma
Kitty Sherwood
United Kingdom
EACR26-0461
P-211
CANCER GENOMICS
Formaldehyde-Induced RUNX1–ISX Axis Drives Leukemic Reprogramming and Poor Prognosis in Pediatric B-ALL
Li-Ting Wang
Taiwan
EACR26-0565
P-213
CANCER GENOMICS
Clonal evolution and spatial heterogeneity of homologous recombination deficiency in breast cancer
Emma Champneys
United Kingdom
EACR26-0637
P-214
CANCER GENOMICS
Investigating Prostate Cancer Molecular Subtypes at the Single-Cell Level
Calista Tink
United Kingdom
EACR26-0691
P-215
CANCER GENOMICS
Integrative Multi-Omics Profiling Identifies Distinct Molecular Subtypes of Taiwanese Colorectal Cancer
Tsz Wun Fok
Taiwan
EACR26-0837
P-216
CANCER GENOMICS
Longitudinal cfDNA Profiling via Whole Exome Sequencing in Advanced NSCLC Patients
Maria Palmieri
Italy
EACR26-0879
P-217
CANCER GENOMICS
Sex modifies mutational processes and DNA repair–associated mutation accumulation in gastric cancer
Dorit Shweiki
Israel
EACR26-0937
P-218
CANCER GENOMICS
Resolving the Genomic Landscape of Colorectal Cancer in a Hungarian Cohort through Long-Read Sequencing
Kalmar Alexandra
Hungary
EACR26-0957
P-219
CANCER GENOMICS
Investigating the molecular diversity of luminal breast cancer arising in young women
Lorena Musco
Italy
EACR26-1015
P-220
CANCER GENOMICS
Unlocking Same-Cell Biology: Non-Destructive Temporal Profiling and Precision Engineering via FluidFM® Technology
Ludovica Rizzo
Switzerland
EACR26-1017
P-221
CANCER GENOMICS
An optical in vivo CRISPR screen for spatial dissection of tumor microenvironment characterization in colorectal cancer
Antonello De Bari
Switzerland
EACR26-1107
P-222
CANCER GENOMICS
Integrated Whole-Exome Sequencing and DNA Methylation Profiling in Chondrosarcomas
Mariana Souza
Brazil
EACR26-1159
P-224
CANCER GENOMICS
Differential spatial transcriptomic profiles associated with breast cancer progression
Joachim Schmid
United States
EACR26-1407
P-225
CANCER GENOMICS
Comprehensive Profiling of Copy Number Instability Signatures Uncovers Distinct Mechanisms of Genomic Instability in Stage I Epithelial Ovarian Cancer: results from retrospective multicentric cohort
Federica Cetti
Italy
EACR26-1423
P-226
CANCER GENOMICS
Investigation of treatment resistance in preclinical models of Colorectal Cancer (CRC) using chromatin accessibility profiling
Vittorio Battaglieri
Italy
EACR26-1431
P-227
CANCER GENOMICS
Ancestry-associated genomic instability patterns in triple negative breast cancer
Bertha Rueda-Zarazua
United Kingdom
EACR26-1449
P-228
CANCER GENOMICS
Transcriptional Reprogramming Associated with Y Chromosome Loss in Mesothelioma
Nikolett Kitti Dobos
Hungary
EACR26-1469
P-229
CANCER GENOMICS
Characterization of a comprehensive landscape of genomic alterations in rare pediatric tumor cell lines
Tim Ludovicy
Germany
EACR26-1615
P-230
CANCER GENOMICS
Clinical classification of germline copy number gain variants of BRCA1, ATM, and TP53 through functional studies
Viktoria Kovacs
Hungary
EACR26-1617
P-231
CANCER GENOMICS
Comprehensive expression profiling of penile cancer
Ruprecht Kuner
Germany
EACR26-1733
P-233
CANCER GENOMICS
Defining the Timeline and Genomic Fingerprints of Therapy-Induced Mutagenesis in Childhood Cancer
Mehdi Layeghifard
Canada
EACR26-1761
P-234
CANCER GENOMICS
Three-dimensional multimodal spatial profiling reveals functional tumor niches in lung cancer
Tancredi Massimo Pentimalli
Germany
EACR26-1811
P-235
CANCER GENOMICS
Laterality-associated genomic alterations in colorectal cancer: Comprehensive profiling of a Brazilian two-center series
Gabriel Bandeira do Carmo
Brazil
EACR26-1823
P-237
CANCER GENOMICS
Non-Invasive Detection of PIK3CA Mutations in Urinary ctDNA Reveals Prognostic Associations in Bladder Cancer
Edyta Borkowska
Poland
EACR26-1919
P-241
CANCER GENOMICS
Decoding TNFR-driven long non-coding RNA functions to design new therapeutics for treatment-refractory cancers
Yinghui Li
Singapore
EACR26-1941
P-242
CANCER GENOMICS
BDNF-Receptor Signalling Modulates Tight Junction Plasticity to Promote Breast Cancer Cell Transmigration Across the Blood-Brain Barrier
Milad Eshmela
United Kingdom
EACR26-1943
P-243
CARCINOGENESIS
Evaluation of the carcinogenic properties of radiofrequencies from wireless communications
Thierry DOUKI
France
EACR26-0055
P-244
CARCINOGENESIS
Role of Mitochondrial Functionality in Chromosomal Stability in Lynch Syndrome
Martyna Salciute
Finland
EACR26-0087
P-245
CARCINOGENESIS
DNA adducts induced by Bisphenol A diglycidyl ether (BADGE), a major ingredient of epoxy resins
Thierry Douki
France
EACR26-0301
P-246
CARCINOGENESIS
Sex-specific translational control in EZH2-driven melanoma tumorigenesis
Andrea Kelemen
Switzerland
EACR26-0457
P-247
CARCINOGENESIS
Deficiency of MET S1014 phosphorylation increases susceptibility to radiation-induced colon tumorigenesis in vivo
Sofiane Bouteiller
Switzerland
EACR26-0459
P-248
CARCINOGENESIS
Functional–genomic dissection of DNA double-strand break repair pathway choice defines polymerase theta inhibitor sensitivity in high-grade serous ovarian cancer
Aleksandra Kruglikov
United Kingdom
EACR26-0543
P-249
CARCINOGENESIS
Investigating a Pro-tumourigenic Role for FKBPL in Oesophageal Adenocarcinoma
Claudine Duggan
Ireland
EACR26-0685
P-250
CARCINOGENESIS
Eosinophils for the prevention of Oesophageal Adenocarcinoma
Maria del Carmen Velasco Martinez
United Kingdom
EACR26-0923
P-251
CARCINOGENESIS
Targeting lncRNA PVT1 as a core modulator of chromatin remodeling and DNA damage response in breast cancer
Viola Melone
Italy
EACR26-1043
P-252
CARCINOGENESIS
A patient-matched organoid platform for HGSOC: modelling the molecular evolution of HRD and therapy resistance
Elisa Marzaroli
Italy
EACR26-1053
P-253
CARCINOGENESIS
Hepatitis B virus large surface protein increases multiple drug resistance (MDR1)-mediated drug efflux by inducing endoplasmic reticulum (ER) stress
Wenya Huang
Taiwan
EACR26-1271
P-254
CARCINOGENESIS
PARP Trapping as a Therapeutic Vulnerability in ARID1A-Deficient Ovarian Clear Cell Carcinoma
Rebecca Tate
United Kingdom
EACR26-1699
P-255
CARCINOGENESIS
Assessing the roles of ARID1A and AAG in the alkylation-induced UPR in ovarian clear cell carcinoma
Laura Balaguer
United Kingdom
EACR26-1701
P-256
CARCINOGENESIS
Uncovering critical DNA damage response (DDR) factors in Ewing sarcoma.
Esther Cruz Zambrano
Spain
EACR26-1707
P-257
CARCINOGENESIS
Quantitative Mapping of Protein–Protein Interactions During DNA Double Strand Break Repair
Elin Enervald
Sweden
EACR26-1765
P-258
DRUG RESISTANCE
Expression of Occludin (OCLN), a tight junctional molecule, in ovarian cancer and association with clinical outcome and response to drug therapies
Anli Xu
United Kingdom
EACR26-0025
P-259
DRUG RESISTANCE
Transcriptional Upregulation of ERG11, MDR1, and CDR1 Genes in Azole Resistance Among Candida Species from Head and Neck Cancer Patients
RANU CHORASIA
India
EACR26-0115
P-260
DRUG RESISTANCE
Protein synthesis and MUC5AC expression are required for chemoprotection in mucinous colorectal adenocarcinomas.
Xiangxu Kong
China
EACR26-0121
P-261
DRUG RESISTANCE
Identification of Functional Protein Targets in Gemcitabine-resistant Pancreatic Ductal Adenocarcinoma using Lysine Crotonylation Profiling
Alfred Long Hin Suen
Hong Kong, China
EACR26-0133
P-262
DRUG RESISTANCE
EPIGENETIC REGULATION OF ACLY-MDR1 AXIS IN COLORECTAL CANCER VIA VITAMIN C
Ana Garcia Bautista
Spain
EACR26-0141
P-263
DRUG RESISTANCE
Mapping Resistance and Pre-Sensitization to FLT3 Inhibitors in Acute Myeloid Leukemia Using Single-Cell Lineage Tracing
Johanna Eriksson
Finland
EACR26-0181
P-264
DRUG RESISTANCE
Genome-wide CRISPR-Cas9 knockout screen of three-dimensional (3D) cancer spheroids identifies therapeutic targets to reverse 3D-specific chemoresistance to Etoposide
Jue Shi
Hong Kong, China
EACR26-0309
P-265
DRUG RESISTANCE
The MALAT1/miR-155 ceRNA circuit drives chemo-immunoresistance in NSCLC via C/EBPβ isoform switching and metabolic rewiring
Niloufar Jafari
Italy
EACR26-0311
P-266
DRUG RESISTANCE
Distortion of the Fallopian Tube Cell-State Trajectory Drives NF-κB–Mediated Chemoresistance in Ovarian Cancer
Anna Pirttikoski
Finland
EACR26-0323
P-267
DRUG RESISTANCE
Effect of TME stiffness on intratumor nuclear heterogeneity and chemoresistance in mTNBC
Elina Mäntylä
Finland
EACR26-0381
P-268
DRUG RESISTANCE
Oxaliplatin causes RNA damage by multiple mechanisms
Zornitsa Kotopanova
United Kingdom
EACR26-0469
P-269
DRUG RESISTANCE
Decoding drug-tolerant persisters in neuroblastoma: insights into resistance to DDR inhibitors
Valeria Elisa Marotta
United Kingdom
EACR26-0473
P-270
DRUG RESISTANCE
Characterization of the HuR-mediated transcriptional landscape in EGFR-TKI resistant NSCLC cells
Annarita Cascone
Italy
EACR26-0495
P-271
DRUG RESISTANCE
Vertical RAS(ON) and MEK blockade Prevents ERK Reactivation and Induces Durable Tumor Control in NF1-Associated Peripheral Nerve Tumors
Sara Mainardi
Netherlands
EACR26-0611
P-272
DRUG RESISTANCE
Intra-patient heterogeneity in PARP inhibitor distribution and response is driven by lysosomal drug accumulation
Carmen Ramirez Moncayo
United Kingdom
EACR26-0639
P-273
DRUG RESISTANCE
Combination therapy with RAS and YAP/TEAD inhibitors overcomes phenotypic cell plasticity-driven resistance in NRAS-mutated melanoma
Mira Kahil
France
EACR26-0661
P-275
DRUG RESISTANCE
Restoration of homologous recombination and replication fork stability as mechanisms of olaparib resistance in in vivo models of ovarian carcinoma
Ilaria Mengoli
Italy
EACR26-0679
P-276
DRUG RESISTANCE
Characterizing the anti-androgen response in prostate cancer cells with multi-modal proteomics: uncovering mechanisms enabling residual disease
Erika Aikio
Finland
EACR26-0719
P-277
DRUG RESISTANCE
Transcriptional Characterization Reveals Intrinsic immunity and Inflammatory Programs Drive Drug-Tolerant Persister Cell States in TNBC
Carla Mayans Gil
Spain
EACR26-0737
P-278
DRUG RESISTANCE
Discovery of Novel VEGFR2 Kinase Inhibitor with Potent Antiproliferative Activity in EGFR-TKI Resistant NSCLC Cells
Sang Kook Lee
South Korea
EACR26-0791
P-279
DRUG RESISTANCE
CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism through the interaction with the SFPQ/p54nrb splicing complex
Valentina Rossi
Italy
EACR26-0807
P-280
DRUG RESISTANCE
Adamantane–Sclareol Hybrids Reverse P-gp-Mediated Drug Resistance through Redox Disruption in Glioblastoma
Ema Lupšić
Serbia
EACR26-0919
P-281
DRUG RESISTANCE
A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer
Alessia Centonze
Spain
EACR26-0987
P-282
DRUG RESISTANCE
GlycoRNAs determine the efficacy of RNA-targeting chemotherapy in colorectal cancer
John Knight
United Kingdom
EACR26-0989
P-283
DRUG RESISTANCE
Targeting mitochondrial fragmentation overcomes proteasome inhibitor resistance in multiple myeloma
Nicola Amodio
Italy
EACR26-1031
P-284
DRUG RESISTANCE
UPR/ATF4/Noxa pathway over-activation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids
Monique N'Diaye
France
EACR26-1139
P-285
DRUG RESISTANCE
Enhancing the Efficacy of Immune Checkpoint Blockade and PI3Kγ Inhibition by Modulated Electro-Hyperthermia in a Colorectal Cancer Model
Mohamed Elsalahaty
Hungary
EACR26-1153
P-286
DRUG RESISTANCE
FAM111B promotes gemcitabine resistance through immune evasion by suppressing T cell recruitment
Juhyang Lee
South Korea
EACR26-1257
P-287
DRUG RESISTANCE
Metabolic Rewiring Drives Resistance to PARP Inhibitors in High Grade Serous Carcinoma
Shabnaz Koochakkhani
Finland
EACR26-1331
P-290
DRUG RESISTANCE
Identification of regulatory mechanisms driving acquired resistance to olaparib in ovarian cancer
Carlos Fernandez-Lozano
Spain
EACR26-1361
P-291
DRUG RESISTANCE
Acquired temozolomide resistance drives a stem-like state in glioblastoma that is vulnerable to BET protein targeting
Raquel López-Rosa
Spain
EACR26-1511
P-293
DRUG RESISTANCE
Modulation of ER Stress Abrogates Chemotherapy Resistance in Triple-Negative Breast Cancer
Dong-Hee Kang
South Korea
EACR26-1557
P-294
DRUG RESISTANCE
Dissecting resistance to bispecific T-cell engagers and the regulation of the target-antigen CEA with genome wide CRISPR screens in CRC organoids
Marta Buzzetti
United Kingdom
EACR26-1561
P-295
DRUG RESISTANCE
Proteomic Mapping Reveals Mitochondrial Gating and a Persister-Like State in Acquired Gemcitabine Resistance of Isogenic PANC-1 Pancreatic Cancer Cells
Ayşe Begüm Ceviz Çubukçuoğlu
Turkey
EACR26-1593
P-296
DRUG RESISTANCE
Development of new class of DNA mimics to circumvent resistance to TOP1 inhibitors
Reem Bannout
France
EACR26-1595
P-297
DRUG RESISTANCE
Effects of Methylglyoxal Stress on Extracellular Matrix Remodeling in Gemcitabine-Resistant Pancreatic Cancer
Akeila BELLAHCENE
Belgium
EACR26-1655
P-298
DRUG RESISTANCE
Nuclear IFITM3 is a co-factor of DNA repair through Non-Homologous End-Joining in healthy and malignant haematopoiesis
Giovanni Crivicich
Italy
EACR26-1671
P-299
DRUG RESISTANCE
Repurposed valproic acid and simvastatin enhance enzalutamide activity in metastatic castration-resistant prostate cancer models
Laura Grumetti
Italy
EACR26-1717
P-301
DRUG RESISTANCE
HDAC9-Mediated Early Emergence of Drug-Tolerant Persister Phenotypes in Bladder Cancer Under Chemotherapeutic Stress
Mateusz Psurski
Poland
EACR26-1789
P-302
DRUG RESISTANCE
Combination Treatment Targeting Cancer Stem Cell Subpopulation Reverting Chemoresistance in Germ Cells Tumors
Natália Udvorková
Slovakia
EACR26-1831
P-303
DRUG RESISTANCE
Design, Synthesis And Biological Evaluation of Efflux-Resistant Topoisomerase I Inhibitors for Use as ADC Payloads
Priantha Pretheshan
United Kingdom
EACR26-1929
P-304
EPIGENETICS
Regulatory miRNAs Controlling Ovarian Cancer Stemness and Recurrence
Ece GUMUSOGLU-ACAR
Turkey
EACR26-0123
P-305
EPIGENETICS
A novel circRNA regulating PI3K signaling in oral cancer progression
Yi-Tung Chen
Taiwan
EACR26-0145
P-306
EPIGENETICS
Decoding the cancer DNA methylome from liquid biopsies: genome-scale methylation profiling for early detection and precision oncology
Aniruddha Chatterjee
New Zealand
EACR26-0159
P-307
EPIGENETICS
Epigenetic rewiring of YAP signaling promotes tumor malignancies
Wei-Chien Yuan
Taiwan
EACR26-0231
P-308
EPIGENETICS
KMT2C Alterations in Osteosarcoma
Yunmi Ko
South Korea
EACR26-0351
P-309
EPIGENETICS
Therapeutic potential of targeting Processing-Bodies in Metabolic Dysfunction-Associated Steatohepatitis and hepatocellular carcinoma
Noémie Gellée
France
EACR26-0455
P-311
EPIGENETICS
Gut microbiota modulation of epigenetic target EHMT2: Lacticaseibacillus rhamnosus Fb7-311 regulated renal cell carcinoma apoptosis
Jeongmin Lee
South Korea
EACR26-0527
P-312
EPIGENETICS
Niclosamide ethanolamine suppresses epithelial-mesenchymal transition through G9a-mediated epigenetic activation of autophagy in lung cancer
I-Ying Kuo
Taiwan
EACR26-0625
P-313
EPIGENETICS
Crosstalk between DOT1L and the Mediator complex regulates glioblastoma stem cell growth
Samir Assaf
Canada
EACR26-0783
P-314
EPIGENETICS
Genome-Wide Methylome Profiling Reveals Epigenetic Heterogeneity within NSMP Endometrial Carcinomas
Laura Poppi
Italy
EACR26-0863
P-315
EPIGENETICS
Multi-Study Analysis of Methylation Landscapes and Biomarkers in ER-positive and ER-negative Breast Cancers
Otilia Menyhart
Hungary
EACR26-0949
P-316
EPIGENETICS
Identification of epigenetic profiles in neuroendocrine neoplasms of different organ sites
Stephanie Roessler
Germany
EACR26-1033
P-317
EPIGENETICS
Multi-omic characterization of KDM3B identifies a potential epigenetic vulnerability in ER-positive breast cancer
Giovanni Nassa
Italy
EACR26-1045
P-318
EPIGENETICS
Quantitative profiling of nuclear MCT1 in endometrial cancer models
Jakub Franczak
United Kingdom
EACR26-1241
P-319
EPIGENETICS
U2AF1 Preserves Genomic Stability in Hepatocellular Carcinoma by Resolving R-Loop Accumulation Through a Spliceosome-Independent Mechanism
Seong Hee KIM
South Korea
EACR26-1245
P-320
EPIGENETICS
METTL16 uncouples global m6A abundance from DNA damage signalling in hepatocellular carcinoma
Yunwon Jang
South Korea
EACR26-1247
P-321
EPIGENETICS
Integrated 3D genome, transcriptome and proteomic assays – simultaneously visualization of genome architecture and gene expression activity in situ at single-cell resolution
Thomas Campbell
United States
EACR26-1261
P-322
EPIGENETICS
Exploiting the BRPF1-ASH1L Functional Co-Dependency as a Therapeutic Strategy in Endocrine-Resistant Breast Cancer
Annamaria Salvati
Italy
EACR26-1329
P-324
EPIGENETICS
Global DNA hypomethylation connected to decreased methyl-donor level in colorectal cancer progression
Krisztina Szigeti
Hungary
EACR26-1447
P-325
EPIGENETICS
MYCN-dependent metabolic reprogramming coordinates chromatin accessibility in neuroblastoma
Tong Zhao
Ireland
EACR26-1635
P-326
EPIGENETICS
Assessment of Illumina 5-base sequencing for integrated methylation and variant analysis in FFPE samples and tumor-informed MRD applications
Nadia Sedlyarova
United States
EACR26-1709
P-327
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
In-silico identification of flavonoid based inhibitors of glucose 6 phosphate dehydrogenase targeting cancer redox metabolism
Deepak K
India
EACR26-0047
P-329
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Discovery of Deoxyadenosine Analogue as an Orally Bioavailable ADAR1 Modulator
Youhong Hu
China
EACR26-0099
P-330
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Proteomic profiling reveals coordinated up- and downregulation of oncogenic and stress response pathways following treatment with a novel magainin bioactive peptide in leukaemia cell models.
Ruth Dogwul Gyereh
United Kingdom
EACR26-0131
P-331
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of Benzothiazole-Based Stimuli-Responsive Photosensitizers
Jeeyeon Lee
South Korea
EACR26-0227
P-332
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Unraveling the anti-cancer potential of Glabrescione B in Intrahepatic Cholangiocarcinoma
Savino Paradiso
Italy
EACR26-0251
P-334
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Regulatory effects of carnosine and carnosine multi-nanoparticles on myelosuppression-related indicators in TF-1 cells
Shu-Ling Hsieh
Taiwan
EACR26-0289
P-335
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Therapeutic potential of SR9009 - a synthetic REV-ERB agonist in urothelial bladder carcinoma cell lines
Edyta Reszka
Poland
EACR26-0317
P-336
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting the TNBC tumor microenvironement with human anti-Cathepsin-D Antibody-Drug Conjugates
Gaëlle Guillon
France
EACR26-0377
P-337
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting SRC/YES1 with the novel oral molecule NXP900 delays Osteosarcoma tumor growth and metastatic dissemination
Emma Racineau
France
EACR26-0425
P-338
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Slow-Release HPMA-Gemcitabine Conjugates Possess Superior Therapeutic Efficacy and Modulate Tumor Immune Microenvironment
Marek Kovar
Czech Republic
EACR26-0439
P-339
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Demethylzeylasteral induces pro-apoptotic and anti-migratory effects against medulloblastoma subtypes
Hannah Eastham
United Kingdom
EACR26-0465
P-340
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Inhibiting ALDH1A3 with a novel small molecule inhibitor prevents breast cancer growth and metastasis
Maya MacLean
Canada
EACR26-0475
P-341
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
N-Iminopyridinium Ylides as Chemically Stable Pharmacophores Enabling Targeted Degradation of SMARCA Proteins and Anti-cancer Efficacy
Linghua Meng
China
EACR26-0507
P-342
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The mono-ADP-ribosyltransferase PARP10 promotes the repair of nascent strand DNA gaps through RAD18 mediated Translesion Synthesis to promote genomic stability and tumor resistance to chemotherapy
Claudia Nicolae
United States
EACR26-0535
P-343
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A spheroid-based pharmacological screening approach identifies a phenothiazine compound as a promising novel adjuvant drug candidate to standard chemotherapies in gastric cancer
Clara Gouez
France
EACR26-0583
P-344
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
In vitro 3D cancer models for deciphering ADC-directed killing: uPAR ADC induces a fibroblast-mediated bystander effect
Kim Holmstrøm
Denmark
EACR26-0585
P-345
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Modeling Response, Resistance Mechanisms, and Immune Interactions to TROP2- and FRα-Targeted ADCs Using Patient-Derived HGSC Long-Term Organoids
Kürşat Birgin
Finland
EACR26-0657
P-346
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Preclinical Evaluation of Novel Imipridones: Potent and Selective Antitumor Activity In Vitro and In Vivo
Ivan Ranđelović
Hungary
EACR26-0663
P-347
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of Vascularized Three-Dimensional Tumoroid Models Using Microphysiological Systems
Arturo Castro Nava
Germany
EACR26-0677
P-348
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Establishment and High-Throughput Drug Screening of Sub-Saharan African Ancestry Prostate Cancer Patient-Derived Cell Lines to Address Underrepresentation in Preclinical Research
Carla Sofia Santos
Portugal
EACR26-0689
P-349
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The proteasome activator subunits PA28a and PA28b have distinct roles in glioblastoma
Kyle Heemskerk
Canada
EACR26-0735
P-350
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
HER3 Expression in Human Placenta and Regulated Interaction with HER3-Targeted Nanotherapeutics Implicates Safety Considerations for Cancer Therapy During Pregnancy
Amirhesam Babajani
United States
EACR26-0757
P-351
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Targeting the Invasive Phenotype Through Metabolic Rewiring
Kateřina Hönigova
Czech Republic
EACR26-0833
P-353
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Precision Targeting MT1-MMP with BT1769: A Bicycle Drug Conjugate (BDC)
Maximilian Harman
United Kingdom
EACR26-0877
P-355
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Repurposing EGLN1 inhibitors for KRAS-mutated lung cancer: a novel strategy targeting mitochondrial fitness
Valentina Sancisi
Italy
EACR26-0907
P-356
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Liposomal Combination of Cannabidiol and Celecoxib Exhibits Anti-Cancer Effects in U-87 MG Cells and Xenograft Model
Anna Rybarczyk
Poland
EACR26-0933
P-357
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
High-Throughput Capillary Immunoassays Enable Precise Quantitation of Protein Degrader Potency and Kinetics in Oncology Discovery
Nico Dankbar
Germany
EACR26-0955
P-358
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Developing an imaging-based ex vivo drug screening platform for paediatric cancer using neuroblastoma as a model
Fern Jenkins
United Kingdom
EACR26-0971
P-360
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Super Enhancers Regulate Growth and Viability of Cutaneous Squamous Carcinoma Cells
Josefiina Haalisto
Finland
EACR26-1003
P-361
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
DNA-based degraders for targeting oncogenic transcription factors
Hannes Halpick
Germany
EACR26-1005
P-362
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Ex vivo drug testing in metastatic biopsies reveals individual vulnerabilities to immunotherapies and antibody-drug conjugates
Christian Werno
Germany
EACR26-1027
P-365
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
PHOENIX: Precision Light-Mediated Delivery of Next-Generation Xanthenium-based Chemotherapy
Verena Handl
Austria
EACR26-1035
P-366
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Overcoming non-genetic resistance in ALK-rearranged NSCLC by targeting ERBB2-driven drug tolerant cells with CAR-T therapy
Riccardo Taulli
Italy
EACR26-1041
P-367
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Hinokitiol Attenuates Uterine Leiomyoma Progression Through Oxidative Stress-Induced DNA Damage, Apoptosis, and Autophagy-Mediated ECM Regulation
Shih-Min Hsia
Taiwan
EACR26-1071
P-368
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A first-in-human trial in advanced liver cancer guided by an in vivo CRISPR screen
Siying Wang
China
EACR26-1093
P-369
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Andrographis paniculata suppresses cancer stem cell-driven ovarian cancer metastasis via Wnt/β-catenin signaling
Weiyu Yu
Hong Kong, China
EACR26-1119
P-370
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Carbonic Anhydrase IX inhibitors as a new therapeutic strategy in multiple myeloma
Arianna Giacomini
Italy
EACR26-1129
P-371
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Reducing Lipotoxicity and Oxidative Stress in the NASH-HCC Microenvironment via Hepatic Stellate Cells-Targeted Nanocarriers to Overcome Sorafenib Resistance
Melis Ercelik
Turkey
EACR26-1185
P-372
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
ERK1/2 Inhibition Sensitizes AML Cells to the Anthrax Lethanl Toxin-Induced MEK Inhibition
Ralph Abi-Habib
Lebanon
EACR26-1203
P-373
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Inhibition of JAK2 and FLT3 exerts antitumor efficacy in hepatocellular carcinoma
Jisoo Kim
South Korea
EACR26-1307
P-374
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Utilising CRISPR-Cas technologies to identify non-coding lncRNA dependencies in high-risk MLL-rearranged acute myeloid leukaemia
Steven He
Australia
EACR26-1311
P-375
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A First-in-Class Engineered Extracellular Vesicle Therapeutic Delivering miR-885-5p Targets the Metastasis Driver LCP-1 in Triple-Negative Breast Cancer
Marianna Prokopi
Cyprus
EACR26-1343
P-376
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Overcoming Therapeutic Resistance in Non-Small Cell Lung Cancer via Covalent Engagement of EGFR Cysteine 775
Richard Anthony Noble
United Kingdom
EACR26-1357
P-377
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Regulation of intracellular cholesterol transporters, Metastatic Lymph Node-64 (MLN64) and StarD3NL and Cellular Cholesterol by Bazi Bushen and compound derivatives, the impact on cell barrier functions
Amber X Li
United Kingdom
EACR26-1377
P-378
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Metabolic Determinants of Imatinib Exposure: Role of L-Carnitine in Chronic Myeloid Leukemia
Marwa S. Hamza
Egypt
EACR26-1445
P-379
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Inhibition of POLRMT reveals mitochondrial transcription as a synthetic lethal target in MYC-driven neuroblastoma
Vojtech Bartovsky
Czech Republic
EACR26-1487
P-380
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Beyond Limits: Next-Generation Spatiotemporal Iontronic Drug Delivery
Christian Bayer
Austria
EACR26-1493
P-381
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
A Tankyrase Inhibitor TI-63174 Suppresses Colorectal Cancer Growth via β-Catenin Modulation and Oxidative Stress
Jiyeon Ahn
South Korea
EACR26-1507
P-382
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Platinum(IV)–Caffeic Acid Derivative Conjugate, Free and SBA-15 Immobilized, as a Multitargeted Therapeutic Strategy in Colorectal Cancer
Vuk Gordić
Serbia
EACR26-1545
P-383
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Rational drug combinations and tumor infiltrating lymphocytes enhance the activity of PARP inhibitors in colorectal cancer organoids
Ida S. G. Strømsvåg
Norway
EACR26-1579
P-384
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
The challenges of performing ring test studies to evaluate the efficacy of complex drug combinations in vitro
Veronica Barile
Italy
EACR26-1619
P-385
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Preclinical Evaluation of the FAP-Targeted Immunoconjugate OMTX705 Reveals Stromal-Mediated Bystander Activity in Sarcoma Patient-Derived Xenografts
Paula Gilabert Prieto
Spain
EACR26-1623
P-386
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
DNA methylation and PI3K/AKT signaling outcomes following CAP exposure
Catarina Almeida-Ferreira
Portugal
EACR26-1645
P-387
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Novel mitochondria-targeted KCa3.1 inhibitors impair tumor cell survival and migration
Héctor Noguera Hurtado
Germany
EACR26-1649
P-388
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Our recent results regarding the use and mechanisms of modulated electro-hyperthermia (mEHT) in a triple-negative breast cancer (TNBC) mouse model
Peter Hamar
Hungary
EACR26-1665
P-389
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of a microRNA-regulated cell death-inducing gene therapy for Acute Lymphoblastic Leukemia
Catarina Godinho
Portugal
EACR26-1773
P-391
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Integrative Transcriptomics and Patient-Derived Organoid Models Identify PI3K Pathway Biomarkers and Therapeutic Candidates in Ovarian Cancer
Emine Kazanc
Turkey
EACR26-1865
P-394
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Perturbation of codon-specific mRNA translation reshapes MHC-II tumor antigen presentation
Pierre CLOSE
Belgium
EACR26-1873
P-395
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Therapeutic efficacy of an EGFRvIII-Retargeted, IL-12-Expressing oncolytic HSV for the treatment of glioblastoma
Antonella Di Loreto
Italy
EACR26-1879
P-396
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Development of a doxorubicin resistance model in Her2- and Her2+ breast cancer to analyze potential therapy targets and drug delivery methods.
Hanna Dams-Kozlowska
Poland
EACR26-1897
P-397
EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Selective JAK1 Targeting by Novel Biotinylated Isoxazoles Drives Potent Antitumor Activity in 2D and 3D Spheroid Models
Melike Ergüven
Turkey
EACR26-1905
P-398
IMMUNOTHERAPY
Decoding Early CAR-T Cell Signaling Networks: Integrating Proteomics, Phosphoproteomics, and Structural Insights
John Oluwafemi Teibo
Brazil
EACR26-0021
P-400
IMMUNOTHERAPY
Real world outcomes of immunotherapy for patients with endometrial cancer
Bethan Stanley
United Kingdom
EACR26-0035
P-401
IMMUNOTHERAPY
In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I–dependent tumor clearance and immune memory
Frederic Tangy
France
EACR26-0039
P-402
IMMUNOTHERAPY
An Immune Checkpoint on the Vasculature: CD160 Regulates Angiogenesis and Tumor Immunity
Abdelilah AZIZ
Morocco
EACR26-0119
P-404
IMMUNOTHERAPY
Combination therapy of proton irradiation and anti-PD-L1 antibody promotes an anti-tumor immunity in pancreatic cancer models
Ho Yagi
Japan
EACR26-0179
P-406
IMMUNOTHERAPY
Enabling Automated Manufacturing of Gene‑Modified T Cells with Lipid Nanoparticles
Caroline Brandes
Germany
EACR26-0283
P-407
IMMUNOTHERAPY
Balancing potency and cytokine release by modulating T cell engagement in CD38 bispecific antibodies for multiple myeloma
Martina Lutz
Germany
EACR26-0365
P-408
IMMUNOTHERAPY
Targeting BCMA in Multiple Myeloma (MM) by CAR Engineering for development of better CAR T Cells in MM
Ashna Gupta
India
EACR26-0371
P-409
IMMUNOTHERAPY
Tumor-infiltrating immune cells and tumor cell HLA expression as potential predictors of response to PD-1 inhibitor therapy in head and neck cancer patients
Kristóf György Csikó
Hungary
EACR26-0375
P-410
IMMUNOTHERAPY
Fluorescence Potency Assays for Evaluating HER2 CAR T-Cell-Mediated Killing in Cancer Cells
Johny Pires
Netherlands
EACR26-0401
P-411
IMMUNOTHERAPY
Boosting CAR-T efficacy in solid tumors by targeting the hepcidin-iron axis
Manel BELDJILALI
France
EACR26-0405
P-412
IMMUNOTHERAPY
Bystander killing of antigen-negative tumor cells by CD8 CAR-T cells in heterogenous patient-derived colorectal organoids
Raphaël Merand
France
EACR26-0443
P-413
IMMUNOTHERAPY
Selective CD8+ T Cell Stimulation by a PD-1–Targeted IL-15–based Immunocytokine Enhances Antitumor Immunity and Promotes Durable Memory Formation
Vladyslav Mazhara
Czech Republic
EACR26-0451
P-414
IMMUNOTHERAPY
TROCEPT: A tumor-targeted precision immunovirotherapy enabling αvβ6 integrin-positive tumor-localized expression of an immune checkpoint inhibitor following intravenous delivery.
Angela Shibu
United Kingdom
EACR26-0607
P-417
IMMUNOTHERAPY
Arming αβT cell-based Immunotherapies with Overexpression of CCR5 Increases T-cell Migration and thereby Therapeutic Efficacy
Caroline Schwenzel
Netherlands
EACR26-0629
P-418
IMMUNOTHERAPY
Auto-antibodies neutralizing IFNα improve immune checkpoint blockade in patients with melanoma
Anaïs Eberhardt
France
EACR26-0667
P-419
IMMUNOTHERAPY
Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
Hadas Reuveni
Israel
EACR26-0695
P-421
IMMUNOTHERAPY
Functional characterization of a bispecific EGFR/AXL antibody in heterogeneous Head and Neck Squamous Cell Carcinoma
May Portman
Israel
EACR26-0743
P-422
IMMUNOTHERAPY
Immune checkpoint inhibitors in sarcomas: a meta-analysis of progression-free and overall survival from prospective studies of monotherapy and combination regimens
Ottavia Clemente
Italy
EACR26-0885
P-423
IMMUNOTHERAPY
From in vitro to ex vivo screening of virotherapy and APC-mediated vaccines in bladder cancer
Callum Blee
United Kingdom
EACR26-0965
P-424
IMMUNOTHERAPY
Robust heavy chain – light chain pairing solutions for generating clinical bi and multispecific antibodies
Emily Radke
United States
EACR26-1011
P-425
IMMUNOTHERAPY
Integrated tumor microenvironment and systemic immune features associate with response to neoadjuvant chemoimmunotherapy in triple negative breast cancer (TNBC)
Lucía Serrano-García
Spain
EACR26-1055
P-426
IMMUNOTHERAPY
Improving effector cells for CAR-NK immunotherapy against Colorectal Cancer
Marco Cortese
Italy
EACR26-1135
P-428
IMMUNOTHERAPY
Potent T-cell engaging (TCE) single domain antibodies that cross-react with non-human primate (NHP) T-cell Receptor (TCR) as an alternative to CD3 engagement
Kevin Schutz
United States
EACR26-1145
P-429
IMMUNOTHERAPY
Elucidation of the interplay between T cell engagers and the tumor microenvironment using a patient-derived tumor tissue culture platform.
Raffaella Iurlaro
Spain
EACR26-1149
P-430
IMMUNOTHERAPY
Comparative analysis of TCR-mimic TCE and CAR-T formats in targeting low-density KRASG12V/HLA-A*03:01 neoantigens
Benedikt J. Lohnes
Germany
EACR26-1237
P-433
IMMUNOTHERAPY
In vivo Tracking and ddPCR-Based Biodistribution Analysis Reveal Superior Antitumor Activity of Dual TCR–CAR T Cells in a Syngeneic Solid Tumor Model
Semi Hwang
South Korea
EACR26-1249
P-434
IMMUNOTHERAPY
Incorporating disulfide bonds into interleukin-2 to enhance therapeutic efficacy in cancer therapy
Woei-Jer Chuang
Taiwan
EACR26-1251
P-435
IMMUNOTHERAPY
PD-L1 expression predominates in immune cells over tumor cells in prostate cancer tissue from Mexican patients across Gleason Score categories
Jorge Adrian Ramirez de Arellano Sanchez
Mexico
EACR26-1259
P-436
IMMUNOTHERAPY
T-Cell Immunological Synaptosomes: A Cell-Free Immunomodulatory Platform for Durable Anti-Tumor Immunity via Innate Immune Reprogramming
Hyeonhee Lee
South Korea
EACR26-1267
P-437
IMMUNOTHERAPY
Platin-pemetrexed and carboplatin-paclitaxel sustain tumor-reactive CD4 T cell response in advanced non-small-cell lung cancer
Caroline LAHEURTE
France
EACR26-1417
P-440
IMMUNOTHERAPY
INDUCING LEUKAEMIC DIFFERENTIATION TO AUGMENT ANTI LEUKAEMIC T-CELL RESPONSES
Florentia Mousoullou
United Kingdom
EACR26-1519
P-441
IMMUNOTHERAPY
Durable pathological complete response associated with broad vaccine-induced T cell immunity in an MSS mCRC patient treated with PolyPEPI1018 peptide vaccine: a case report from the OBERTO-101 study
Eniko R Tőke
United Kingdom
EACR26-1533
P-442
IMMUNOTHERAPY
Neogenes as shared immunotherapy targets in Ewing sarcoma
Ana Lalanne
France
EACR26-1589
P-443
IMMUNOTHERAPY
Improving CAR T cell therapy of pancreatic cancer by usage of CARs with VHH binders
Alexander Seitz
Germany
EACR26-1609
P-444
IMMUNOTHERAPY
VHH-based Tandem CARs Enable OR-gated multi-targeting of pancreatic cancer
Camille Dourlens
Germany
EACR26-1643
P-445
IMMUNOTHERAPY
Single-Cell Function Driven Screening and Characterization of Bispecific T Cell Engagers
Tiago Santos
United States
EACR26-1703
P-446
IMMUNOTHERAPY
Integrative spatial and immune profiling identifies predictors of response to neoadjuvant anti-PD-1 therapy in NSCLC
Klara Mezerova
Czech Republic
EACR26-1751
P-447
IMMUNOTHERAPY
Preclinical Evaluation of EGFRvIII-Retargeted Oncolytic HSV in Novel Engineered Murine and Human Glioblastoma Platforms
Francesca Piaggio
Italy
EACR26-1769
P-448
IMMUNOTHERAPY
Defining the Role of STK38(L) in Natural Killer Cell Immunity
Faith O. David
Austria
EACR26-1855
P-450
MOLECULAR AND GENETIC EPIDEMIOLOGY
Associations between the gut microbiome and sleep characteristics, insomnia, and fatigue among colorectal cancer patients
Victoria Damerell
Germany
EACR26-0587
P-452
MOLECULAR AND GENETIC EPIDEMIOLOGY
Identification of aggressive differentiated thyroid cancers: an untargeted metabolomics approach
Carlota Castro-Espin
France
EACR26-0613
P-453
MOLECULAR AND GENETIC EPIDEMIOLOGY
Coffee Consumption and Colorectal Cancer Survival: A Meta-Analysis by Coffee Type and Disease Stage
Chang-Gue Son
South Korea
EACR26-1279
P-454
PREVENTION AND EARLY DETECTION
Dose and schedule optimisation of a carcinogen-induced mouse model enables low-toxicity, mechanistically relevant chemoprevention studies in oral cancer.
Sakshi Anchan
India
EACR26-0293
P-455
PREVENTION AND EARLY DETECTION
Immune cell alteration in a metformin-chemoprevention colorectal carcinogenesis mouse model
Mark Molloy
Australia
EACR26-0553
P-456
PREVENTION AND EARLY DETECTION
A p53–SASP axis drives neutrophil-mediated fibrosis in pre-cancerous metabolic dysfunction-associated steatohepatitis.
Liam Butler
United Kingdom
EACR26-0627
P-457
PREVENTION AND EARLY DETECTION
Celastrol-flavanol conjugates from the stems of Tripterygium attenuate pulmonary fibrosis through TGF-beta signaling pathways
Won Keun Oh
South Korea
EACR26-1287
P-458
PREVENTION AND EARLY DETECTION
“Study on Breast Cancer Screening using Thermalytix - AI powered Non-Invasive screening tools”
Thamizholi Selvaraju
India
EACR26-1371
P-460
PREVENTION AND EARLY DETECTION
Preclinical Chemopreventive Activity of Honokiol in Parenteral Nutrition-Associated Liver Injury
Marta Belka
Poland
EACR26-1555
P-462
RADIOBIOLOGY / RADIATION ONCOLOGY
6-[18F]Fluoronicotinic Acid PET Visualizes Intracranial Human Glioblastoma Xenografts that are [18F]FET PET Negative
David Ekwe
Finland
EACR26-0447
P-464
RADIOBIOLOGY / RADIATION ONCOLOGY
Re-sensitising Cervical Cancer to Therapy Through c-ABL Inhibition
Kanchalika Homkajorn
United Kingdom
EACR26-1155
P-465
RADIOBIOLOGY / RADIATION ONCOLOGY
CDK4/6 Inhibition with Ribociclib Enhance Radiotherapy Efficacy in Glioblastoma
Merzuka Kalay
Turkey
EACR26-1775
P-467
SIGNALING PATHWAYS
Application of NanoString technologies in chronic myeloid leukemia, essential thrombocythemia, primary myelofibrosis and polycythemia vera
Chi-Hyun Cho
South Korea
EACR26-0031
P-469
SIGNALING PATHWAYS
CXCL13 Drives Oral Squamous Cell Carcinoma Metastasis via a CXCR5–JNK–NF-κB–MMP9 Signaling Axis
Tsung-Ming Chang
Taiwan
EACR26-0157
P-470
SIGNALING PATHWAYS
Computational and experimental analyses identify indicators of response to the CDC7 inhibitor CRT2199 beyond general drug sensitivity
Hasan Mamar
Hungary
EACR26-0249
P-471
SIGNALING PATHWAYS
Functional analysis of lncRNAs regulating SNAIL
Satoshi Sakai
Japan
EACR26-0505
P-472
SIGNALING PATHWAYS
The CD39-STAT3 axis in Sézary syndrome: emerging molecular biomarkers and therapeutic targets
Liyun Lin
Italy
EACR26-0713
P-473
SIGNALING PATHWAYS
Network-Based Validation of Predicted Upstream Kinases Using Drug Sensitivity Data
Dora Schuller
Netherlands
EACR26-0853
P-474
SIGNALING PATHWAYS
Novel interactions of Mixed-Lineage Kinase 4: identifying key binding partners in breast cancer
Vi Truong
Poland
EACR26-0911
P-475
SIGNALING PATHWAYS
Akt isoforms differentially regulate RhoA signaling and migration of non-small cell lung cancer (NSCLC) cells
Klaudia Giehl
Germany
EACR26-0951
P-476
SIGNALING PATHWAYS
IKKα suppresses colorectal cancer metastasis by maintaining NF-κB-driven expression of the ERK phosphatases DUSP1/5
Dina Harti
Spain
EACR26-1009
P-477
SIGNALING PATHWAYS
NRF1-mediated activation of gene expression promotes cell cycle progression
Louisa Franziska Schmidbauer
Germany
EACR26-1049
P-478
SIGNALING PATHWAYS
Single-molecule super-resolution imaging reveals mutation-specific EGFR oligomerization and differential disruption by osimertinib in NSCLC
Katie Sharrocks
United Kingdom
EACR26-1143
P-479
SIGNALING PATHWAYS
Nck adaptor proteins regulate breast cancer cell metastasis and invasion
Erka Shata
Canada
EACR26-1189
P-480
SIGNALING PATHWAYS
Compensatory Receptor Tyrosine Kinase Signaling Reactivates the RAF–MEK–ERK pathway causing resistance to MEK-inhibition in Glioblastoma.
Mike van Heumen
Netherlands
EACR26-1327
P-481
SIGNALING PATHWAYS
Chromatin remodeler MORC2 transcriptionally regulates tumor suppressor PTEN in breast cancer
Namita Chutani
India
EACR26-1399
P-482
SIGNALING PATHWAYS
A Ras family member mediates reciprocal activation of ERK5 and ERK1/2 signaling in response to inhibition of either pathway
Ignazia Tusa
Italy
EACR26-1463
P-483
SIGNALING PATHWAYS
Loss of Ras feedback regulation triggers oncogenic stress and senescence to suppress JNK-dependent Ras–Yki tumour growth
Shijun Fang
United Kingdom
EACR26-1705
P-485
SIGNALING PATHWAYS
Evolutionarily conserved NOTCH1–PLK1 axis orchestrates DNA damage adaptation and therapy resistance
Giulia Ferrera
Italy
EACR26-1719
P-486
SIGNALING PATHWAYS
Recursive macroscopic coalescence of signal transducers drives kinase, calcium and phosphoinositide signaling for cell growth
Saverio Alberti
Italy
EACR26-1763
P-487
SIGNALING PATHWAYS
Genetic Context-Dependent Regulation of Redox Signalling Determines Ferroptosis Sensitivity in Human Lung Epithelial Cells
Jakub Pawlikowski
Poland
EACR26-1837
P-488
SIGNALING PATHWAYS
Characterization of the Axl/Gas6 signaling pathway following receptor inhibition by peptide ligands and siRNAs
Alexandra Tsal-Tsalko
Austria
EACR26-1849
P-489
SIGNALING PATHWAYS
Receptor-dependent and -independent control of breast cell homeostasis by SSRIs
Iván Uray
Hungary
EACR26-1917
P-490
TRANSLATIONAL RESEARCH
Chemotherapy during pregnancy – a prospective study of short- and long-term cardiac effects
Orly Abramovich
Israel
EACR26-0027
P-491
TRANSLATIONAL RESEARCH
De-risking Translation: Multi-laboratory Confirmation of Preclinical Evidence
Pasquale Pellegrini
Germany
EACR26-0117
P-492
TRANSLATIONAL RESEARCH
Comparison of Different Pathological Regression Classifications Following Neoadjuvant Chemotherapy in Breast Cancer Patients
Gabriella Ivády-Szabó
Hungary
EACR26-0287
P-493
TRANSLATIONAL RESEARCH
Breast malignancies exhibit a distinct bioelectric phenotype detectable by time-domain bioimpedance
Marc Goldfinger
United Kingdom
EACR26-0319
P-494
TRANSLATIONAL RESEARCH
Pregnane X Receptor (PXR) contributes to phenotypic plasticity and modulates the sensitivity to targeted therapies in melanoma
Stefan D. NICOLESCU
France
EACR26-0367
P-495
TRANSLATIONAL RESEARCH
Prognostic and molecular characterization of ALPP-positive colorectal cancer
Ville Äijälä
Finland
EACR26-0441
P-496
TRANSLATIONAL RESEARCH
Clinical translation of epigenetically encoded transcriptional plasticity to unlock cell state precision oncology in glioblastoma
Jakob Ito
United States
EACR26-0545
P-497
TRANSLATIONAL RESEARCH
A charge-convertible, fluorescence-guided nanoplatform for deep tumor penetration and image-guided photodynamic therapy of rectal cancer
Dae-Duk Kim
South Korea
EACR26-0573
P-498
TRANSLATIONAL RESEARCH
STING Beyond Immunity: Tumour-Intrinsic Roles in Breast Cancer Progression and Metastasis
Vaibhavi Joshi
Australia
EACR26-0759
P-499
TRANSLATIONAL RESEARCH
Triple Immune Checkpoint Blockade Induces Immune-Mediated Cardiomyocyte Injury: Translational Implications for Cardio-Oncology Surveillance
Pietro Forte
Italy
EACR26-0767
P-500
TRANSLATIONAL RESEARCH
Postpartum Shapes the Biological and Clinical Features of HR+ Breast Cancer Diagnosed During Pregnancy
Antònia Martí
Spain
EACR26-0869
P-502
TRANSLATIONAL RESEARCH
Sustainable Lignin-Iron Oxide Nanoplatforms for 3D Tumour Spheroids via Magnetic Levitation
Khushboo Pathania
India
EACR26-0939
P-503
TRANSLATIONAL RESEARCH
"Role of Computer Tomography in the evaluation of lung carcinoma and its correlation with histopathological findings".
THAMIZHOLI SELVARAJU
India
EACR26-1037
P-504
TRANSLATIONAL RESEARCH
Rapid AI-Assisted Intraoperative Diagnosis for Biliary Tract Adenocarcinoma Using Femtosecond Laser Label-Free Microscopy
Hui Bai
China
EACR26-1047
P-505
TRANSLATIONAL RESEARCH
Patient-Derived Organoids and Proteotranscriptomic Integration to Identify Therapeutic Vulnerabilities in Chemotherapy-Resistant Advanced Gastric Cancer
Manuel Cabeza-Segura
Spain
EACR26-1065
P-506
TRANSLATIONAL RESEARCH
STABLE 13C AND 15N ABUNDANCE AND FRACTIONATION IN TUMOR CORE, INFILTRATING FRONT, AND HEALTHY SURROUNDING TISSUES OF GLIOBLASTOMA
Maria Teresa Gentile
Italy
EACR26-1083
P-507
TRANSLATIONAL RESEARCH
The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer
Jordane Divoux
France
EACR26-1101
P-508
TRANSLATIONAL RESEARCH
Inductiοn of a ΗRD phenοtype to sensitize ovarian cancer to PARP inhibition by targeting UBE2N : toward the use of repurposed FDA-approved compounds
Matthieu Meryet-Figuiere
France
EACR26-1137
P-509
TRANSLATIONAL RESEARCH
RAGE targeting antibody–drug conjugates as a theranostic treatment strategy for advanced prostate cancer
Daniel Turnham
United Kingdom
EACR26-1161
P-510
TRANSLATIONAL RESEARCH
Multifunctional AIEgen-Loaded MnO2 nanoplatform for tumor microenvironment modulation and cancer therapy
Hirakjyoti Roy
India
EACR26-1165
P-512
TRANSLATIONAL RESEARCH
Local Modulated Electro-Hyperthermia Triggers an Abscopal-Like Anti-Metastatic Effect in 4T1 Triple Negative Breast Cancer Model
Eslam Abdalalem
Hungary
EACR26-1167
P-513
TRANSLATIONAL RESEARCH
Evaluation of oncological safety for the development of human amniotic membrane-based bioactive scaffolds in post-mastectomy breast reconstruction
Ivana Okic Dordevic
Serbia
EACR26-1201
P-515
TRANSLATIONAL RESEARCH
Sclareol-Derived Self-Assembling Nanoparticles: A Nature-Inspired Platform for Overcoming Drug Resistance in Cancer
Ana Stepanović
Serbia
EACR26-1225
P-516
TRANSLATIONAL RESEARCH
Cancer Organoid–Based Diagnostic Response Prediction for Anticancer Therapy and Progression-Free Survival in Lung Cancer
Chan Kwon Park
South Korea
EACR26-1277
P-517
TRANSLATIONAL RESEARCH
Functional drug response in patient-derived organoids highly correlates with pancreatic cancer patient progression-free survival
Abraham Lin
Belgium
EACR26-1313
P-518
TRANSLATIONAL RESEARCH
Comparative analysis of the efficacy and off-target activity of clinical KRAS G12C inhibitors in human lung adenocarcinoma models
Marcell Baranyi
Germany
EACR26-1321
P-519
TRANSLATIONAL RESEARCH
Distinct gut microbiota signatures differentiate breast cancer patients from healthy women, correlate with clinical outcomes, and shift during endocrine therapy.
Maya Dadiani
Israel
EACR26-1365
P-520
TRANSLATIONAL RESEARCH
The OvaCure Collection – world’s largest open biobank of high-grade serous carcinoma organoids
Wojciech Senkowski
Denmark
EACR26-1403
P-521
TRANSLATIONAL RESEARCH
Expanding the boundaries of spatial proteomics with a universal antibody labeling strategy
Thore Boettke
Germany
EACR26-1501
P-523
TRANSLATIONAL RESEARCH
Proteasome inhibition overcomes TRAIL resistance and enhances MSC-sTRAIL activity in malignant pleural mesothelioma
Valentina Masciale
Italy
EACR26-1627
P-524
TRANSLATIONAL RESEARCH
In situ-formed osteosarcoma spheroids in a scaffold-based three-dimensional model under flow conditions: characterization and cytostatic drug response
Ivana Banićević
Serbia
EACR26-1787
P-525
TRANSLATIONAL RESEARCH
SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-selective inhibitor Alpelisib and Fulvestrant Under Hyperglycemia
Pietro Forte
Italy
EACR26-1819
P-527
TRANSLATIONAL RESEARCH
Metabolic Modulation by SGLT2 Inhibitors Canagliflozin and Dapagliflozin: A Novel Strategy to Balance Antitumor Efficacy and Cardiotoxicity in HER2-Positive Breast Cancer Therapy
Pietro Forte
Italy
EACR26-1845
P-528
TRANSLATIONAL RESEARCH
Integrated spatial transcriptomic and proteomic profiling uncovers tumor-immune niches driving heterogeneity and resistance in Clear Cell Renal Cell Carcinoma
Daniela Natale
Italy
EACR26-1923
P-530
TRANSLATIONAL RESEARCH
Novel Genetically Engineered Mouse Model of Ovarian Carcinosarcoma Reveals a Dual Role for Anti Inflammatory Drugs
Einav Girsh
Israel
EACR26-1931
P-531
TRANSLATIONAL RESEARCH
Transcriptional profiling to improve modeling of aggressive endometrial cancers
Hege F. Berg
Norway
EACR26-1939
P-532
TUMOUR BIOLOGY
Mapping Tumour Promoting and Restrictive Subpopulations of Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma
Yihan Xu
United Kingdom
EACR26-0015
P-610
TUMOUR BIOLOGY
HOXC4-upregulated SPP1 in cancer-associated fibroblasts binds to integrin β-1 in colorectal cancer cells to promote metastasis
Huogang Wang
China
EACR26-0033
P-611
TUMOUR BIOLOGY
PDX Models Capturing Enfortumab Vedotin Response Patterns in Bladder Cancer Patients of the UNLOCK Program
Ludovic Bigot
France
EACR26-0097
P-612
TUMOUR BIOLOGY
Alpha-synuclein-mediated immunological signatures in melanoma
Panagiota S. Filippou
Greece
EACR26-0139
P-613
TUMOUR BIOLOGY
circCLASP1 as a Regulator of Cell Survival in Cervical Cancer Cells
İpek Erdoğan-Vatansever
Turkey
EACR26-0153
P-614
TUMOUR BIOLOGY
Evaluation of AV-3 as a Stromal Modulator in Breast Cancer Models
Gohar Sevoyan
Armenia
EACR26-0191
P-615
TUMOUR BIOLOGY
NCL is secreted by cancer cells
Ming Hui Millie Wong
Singapore
EACR26-0195
P-616
TUMOUR BIOLOGY
Estrogen reshapes the tumor microenvironment to promote mesenchymal phenotype
Kyoung-Jin Woo
South Korea
EACR26-0203
P-533
TUMOUR BIOLOGY
Role of tumor-stroma metabolic crosstalk in the resistance to anti-EGFR therapy in head and neck cancers
Engy Vigneron
Belgium
EACR26-0221
P-617
TUMOUR BIOLOGY
Classification of Prostate Cancer Bone Metastasis Subtypes by Proteomics
Dennis Xie
Canada
EACR26-0245
P-534
TUMOUR BIOLOGY
Novel whole transcriptome spatial transcriptomics technology reveals CAF/TAM-mediated basement membrane remodeling at the tumor invasive front
Monica Nagendran
United States
EACR26-0263
P-619
TUMOUR BIOLOGY
Tumor cell expression of Connexin 43 contributes to lung metastasis
Anna La Torraca
Switzerland
EACR26-0275
P-620
TUMOUR BIOLOGY
IFNγ Pathway Activation and Epigenetic Remodelling Constrain Drug-Tolerant Persister Progression and Resistance to CHK1 Inhibition in Neuroblastoma Cells
LeAnne Carmichael
United Kingdom
EACR26-0277
P-535
TUMOUR BIOLOGY
L1CAM/RET Signaling Drives Sunitinib Resistance and Immune Suppression in Renal Cell Carcinoma
Wei-Jiunn Lee
Taiwan
EACR26-0297
P-621
TUMOUR BIOLOGY
From molecular mechanism of palbociclib resistance to potential therapeutic strategies
Pai-Sheng Chen
Taiwan
EACR26-0305
P-622
TUMOUR BIOLOGY
Dissecting Melanoma Cell State Dynamics In Vivo Using a Novel Zebrafish Transgenic Model
Paco Lopez-Cuevas
United Kingdom
EACR26-0341
P-624
TUMOUR BIOLOGY
Optimization of a 3D bioprinted model mimicking breast cancer in the context of obesity
Jessy Aoun
France
EACR26-0363
P-625
TUMOUR BIOLOGY
The tumor metabolite 1-methylnicotinamide (1MNA) disturbs T cell protein homeostasis and leads to an exhaustion phenotype
Lea Vogt
Germany
EACR26-0387
P-536
TUMOUR BIOLOGY
Leveraging the anti-tumoral activity of a combinatorial EVs-miRNA signature against breast and pancreatic cancer models: a novel approach in RNA-based therapies
Guénolé Tossou
France
EACR26-0391
P-537
TUMOUR BIOLOGY
Lighting Up the Dark: Role of melanosomes in melanoma
Jeremy Raymond
United Kingdom
EACR26-0403
P-538
TUMOUR BIOLOGY
Modeling clinically defined precachexia in mice reveals stage-dependent programs during progression to systemic cancer cachexia
JIHO KIM
South Korea
EACR26-0413
P-539
TUMOUR BIOLOGY
Exploring the Potential Role of MXRA5+ Cancer-Associated Fibroblasts (CAFs) in Regulating Esophageal Squamous Cell Carcinoma (ESCC) Progression and Metastasis
Shuang Zhang
China
EACR26-0419
P-626
TUMOUR BIOLOGY
Genome-wide in vivo CRISPR screen identifies PON3 as a modulator of immunotherapy response in hepatocellular carcinoma
Ming Zhu
Hong Kong, China
EACR26-0423
P-540
TUMOUR BIOLOGY
Fucosyltransferase 5 promotes adhesion and angiogenesis of metastatic ovarian cancer cells
Siyu Zhou
Hong Kong, China
EACR26-0491
P-541
TUMOUR BIOLOGY
Fascin-1 Overexpression at Diagnosis is Independently Associated with Right-Sided Location and MSI-High Status in Colorectal Cancer: Results from the HITCLIF Clinical Trial Cohort
Antonio Asensi Cantó
Spain
EACR26-0493
P-627
TUMOUR BIOLOGY
Exploring Therapy-Induced Senescence as a Driver of Prostate Cancer Bone Metastasis Using a Human In Vitro Bone Model
Imen Dziri
Switzerland
EACR26-0515
P-629
TUMOUR BIOLOGY
Optimized Expansion and Co-Culture of Cancer-Associated Fibroblasts with Patient-Derived Tumoroids
Sara Perez Munoz
Spain
EACR26-0517
P-630
TUMOUR BIOLOGY
The Muscle–Tumor Iron Axis: Skeletal Muscle FLVCR1a Controls Metastatic Progression
Paolo Porporato
Italy
EACR26-0521
P-542
TUMOUR BIOLOGY
Influence of TNF-α and IFN-γ on the primary mediastinal B-cell lymphoma cells
Petra Korać
Croatia
EACR26-0523
P-543
TUMOUR BIOLOGY
BATF-Driven T Cell Dysfunction in CCR2⁺ T Cell Subsets within the Lung Tumor Microenvironment
Pin-Yuan Lin
Taiwan
EACR26-0621
P-544
TUMOUR BIOLOGY
Comparative Effects of Cisplatin and Postbiotics on Macrophage Phenotype in Tumor and Normal Microenvironments in Lung Cancer
Ayse Caner
Turkey
EACR26-0631
P-631
TUMOUR BIOLOGY
Targeting GSK-3β reverses CAF-driven immunosuppression and restores anti-PD-1 sensitivity in colorectal cancer
Aurora Rivas Crespo
Spain
EACR26-0643
P-632
TUMOUR BIOLOGY
TROP2-Linked Molecular Signatures in a Colon PCTS–Tumor Spheroid Co-culture Model
Kerstin Huebner
Germany
EACR26-0649
P-633
TUMOUR BIOLOGY
A spatial transcriptomics atlas reveals tumor cell plasticity and recurrent tumor microenvironment structures in Ewing sarcoma
Heng Luo
Germany
EACR26-0693
P-545
TUMOUR BIOLOGY
KRAS/LKB1 co-mutated NSCLC-derived Extracellular Vesicles trigger TLR4-dependent IL-6 induction to drive inflammatory fibroblast reprogramming
Cristina Borzi
Italy
EACR26-0697
P-546
TUMOUR BIOLOGY
Dormant myeloma cells exhibit higher DNA damage levels – a new vulnerability in cancer cell dormancy?
Abigail Foston
United Kingdom
EACR26-0729
P-547
TUMOUR BIOLOGY
ROBO-Slit signaling as a player in melanoma cell migration and therapy resistance
Lea Otte
Germany
EACR26-0747
P-548
TUMOUR BIOLOGY
Stromal contribution in osteosarcoma: the Ephrin A4-BMP4 axis as a tumor-CAF paracrine vicious cycle
Giorgia Giordano
Italy
EACR26-0755
P-549
TUMOUR BIOLOGY
MIF-CD44 crosstalk between TAMs and CAFs drives progression of H. pylori infected microsatellite-stable gastric cancer
Sung bin Cho
South Korea
EACR26-0793
P-550
TUMOUR BIOLOGY
Pulsed matrix priming with enhances treatment response in pancreatic cancer
Kendelle Murphy
Australia
EACR26-0795
P-551
TUMOUR BIOLOGY
LRRC15-Positive Cancer-Associated Fibroblasts Promote Colorectal Cancer Progression through VCAM1 Secretion.
Deok-beom Jung
South Korea
EACR26-0797
P-552
TUMOUR BIOLOGY
A NOVEL ORGAN-ON-CHIP PLATFORM TO MODELING CANCER METASTASIS FOR DRUG DISCOVERY
Lutfiye Yildiz Ozer
Qatar
EACR26-0809
P-553
TUMOUR BIOLOGY
Extracellular vesicles derived from Wharton’s Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway
Yun-Hsuan Chang
Japan
EACR26-0831
P-554
TUMOUR BIOLOGY
Oxidative stress as a novel therapeutic strategy targeting dormant multiple myeloma
Chloe Harris
United Kingdom
EACR26-0839
P-555
TUMOUR BIOLOGY
Shaping the Ganglioside Landscape : TGF-B Driven Remodeling in Human Glioblastoma Cells
Katinka Tarnóczi
France
EACR26-0847
P-556
TUMOUR BIOLOGY
Tks4 as a Liquid–Liquid Phase Separation–Competent Signaling Scaffold Driving Invasive Programs in Carcinoma Cells
Loretta László
Hungary
EACR26-0865
P-558
TUMOUR BIOLOGY
Dual Targeting of tumor cells and tumor-associated macrophages by a CD44-specific RNA aptamer in chemoresistant triple-negative breast cancer
Antonietta Caianiello
Italy
EACR26-0867
P-559
TUMOUR BIOLOGY
BER and MMR converge: decoding 5-methylcytosine deamination repair
Marc-Henri Stern
France
EACR26-0875
P-560
TUMOUR BIOLOGY
Spatiotemporal optical barcoding identifies polyclonal synergism as a driver for lymph node metastasis.
Apostolos Panagiotis Nikolakopoulos
Belgium
EACR26-0881
P-561
TUMOUR BIOLOGY
Decoding the Tumor–Platelet Dialogue: role of platelet-derived EVs in Breast Cancer Progression
Giulia Cosentino
Italy
EACR26-0883
P-562
TUMOUR BIOLOGY
Cancer-associated Fibroblast Composition in Stage III Colon Cancer Correlates with Prognosis and Chemotherapy Resistance
Marin Bont
Netherlands
EACR26-0887
P-563
TUMOUR BIOLOGY
Development of mixed spheroid cultures as a triple negative breast cancer model
Marlene Eder
Austria
EACR26-0889
P-564
TUMOUR BIOLOGY
PDE4 inhibition suppresses invasion and migration in GNAS-mutant colorectal cancer cells
Aparna Ganesan
Finland
EACR26-0897
P-565
TUMOUR BIOLOGY
Oncolytic Viral Therapy Reprograms Macrophages to Overcome ICI Resistance in Prostate Cancer via IL-15–Supported Immune Infiltration
Sunny Sunshine
United Kingdom
EACR26-0929
P-566
TUMOUR BIOLOGY
FAK enables chemotherapy-induced vascular endothelial stress reprogramming and senescence that contributes to lung pre-metastatic niche formation.
Madeleine Benguigui
United Kingdom
EACR26-0963
P-567
TUMOUR BIOLOGY
Peripancreatic Adipose Tissue–Derived Extracellular Vesicles Orchestrate Stress-Adaptive PI3K–AKT Signaling and Central Carbon Metabolism in Pancreatic Cancer
Ankita Arora
India
EACR26-0967
P-568
TUMOUR BIOLOGY
Modulating the RNA-binding protein MEX3A to enhance chemosensitivity in colorectal cancer tumoroid models
Morgana Russel
Portugal
EACR26-1091
P-569
TUMOUR BIOLOGY
Xenograft tissue slice tandem co-cultures as models for ex vivo analyses of glioblastoma invasion or brain metastasis
Achim Aigner
Germany
EACR26-1147
P-571
TUMOUR BIOLOGY
Effect of violacein on tumor growth and dissemination of HCT116 cells in a zebrafish xenograft model
Emilija Milošević
Serbia
EACR26-1173
P-572
TUMOUR BIOLOGY
Identification of cap methyltransferase 1 (CMTR1) as a HIF coactivator
Daiana Leila Drehmer
United States
EACR26-1179
P-573
TUMOUR BIOLOGY
Characterization of novel cancer cachexia preclinical models implementing chemotherapy and surgery
Claudia Fornelli
Italy
EACR26-1197
P-574
TUMOUR BIOLOGY
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) drives pericyte activation supporting breast cancer progression
Marianna Moro
Italy
EACR26-1207
P-575
TUMOUR BIOLOGY
Epithelial-derived signals orchestrate functional CAF activation in the colorectal cancer tumor system
Noemi Russo
Italy
EACR26-1309
P-576
TUMOUR BIOLOGY
Tumor-derived extracellular matrix is essential for breast cancer initiation
Johanna Englund
Finland
EACR26-1333
P-577
TUMOUR BIOLOGY
Functional and Metabolic Reprogramming in Tumour-Educated Platelets drive Thyroid Cancer Progression
Srabonti Ghosh
India
EACR26-1395
P-578
TUMOUR BIOLOGY
Senescence and epithelial plasticity drive replication stress‑induced persistence in colorectal cancer
Shahab Majidi
Italy
EACR26-1419
P-580
TUMOUR BIOLOGY
Development of a chick chorioallantoic membrane co-culture model to recapitulate the hepatic metastatic microenvironment of uveal melanoma
Jayanti Jha
United Kingdom
EACR26-1461
P-582
TUMOUR BIOLOGY
HeyL, a Notch downstream target, is upregulated in BRAFV600E-driven papillary thyroid cancer
Sima Kumari
Sweden
EACR26-1505
P-583
TUMOUR BIOLOGY
Establishment and Characterisation of Novel Patient-Derived Pancreatic Cancer Cell Lines
Olga Chodelkova
Slovakia
EACR26-1523
P-584
TUMOUR BIOLOGY
Deciphering the relation between CEMIP and inflammation in the context of cutaneous melanoma
Maria Larrinaga
Spain
EACR26-1525
P-585
TUMOUR BIOLOGY
Transcription factor EB modulation in endothelium affects lung cancer metastatization
Sara Pastorello
Italy
EACR26-1541
P-586
TUMOUR BIOLOGY
The role of Activin-A in shaping cancer-associated fibroblast identity and pancreatic ductal adenocarcinoma aggressiveness
Evangelia Papadopoulou
France
EACR26-1559
P-587
TUMOUR BIOLOGY
Phosphatidylserine-positive extracellular vesicles: key drivers of cellular communication in the tumor microenvironment
Klára Hánělová
Czech Republic
EACR26-1569
P-588
TUMOUR BIOLOGY
Spatial Transcriptomic and Proteomic Profiling of H3K27M Diffuse Midline Gliomas Reveals a Myeloid-Dominant, Immune-Cold Tumour Microenvironment
Ilaria Serangeli
Italy
EACR26-1575
P-589
TUMOUR BIOLOGY
Apoptotic Cell–Driven Tumor Microenvironment Remodeling in a Mixed Inoculation Model of Colorectal Cancer
Sanja Mijatović
Serbia
EACR26-1577
P-590
TUMOUR BIOLOGY
Modelling the Mesenchymal Breast Cancer Microenvironment Using Low-Shear 3D Culture and Physioxia
Helle Sedighi Frandsen
Denmark
EACR26-1591
P-591
TUMOUR BIOLOGY
Tackling the role of the immune tumor microenvironment in pediatric melanoma progression
Sofia Carvalho-Marques
Portugal
EACR26-1599
P-592
TUMOUR BIOLOGY
Lipid Desaturation as a Metabolic Checkpoint for T cell Immunity Suppression in Liver Cancer
Nicolae Ciobu Zubenco
United States
EACR26-1625
P-594
TUMOUR BIOLOGY
Multi-Source Proteomics Uncovers Early Cardiac Remodeling in Cancer Cachexia
Edina Bugyik
Hungary
EACR26-1629
P-595
TUMOUR BIOLOGY
Characterizing CD36-Driven Lipid Exchange in Melanoma–Adipocyte Crosstalk Mediated by Extracellular Vesicles
Gaia Giannitti
Italy
EACR26-1679
P-596
TUMOUR BIOLOGY
Characterization of eNAMPT as a Pro-Tumorigenic Factor and Potential Pharmacological Target in Ovarian Cancer
Margherita Destefanis
Italy
EACR26-1687
P-597
TUMOUR BIOLOGY
Optical pooled screens in the colon cancer TME
Andreas Moor
Switzerland
EACR26-1713
P-598
TUMOUR BIOLOGY
Development and validation of multiplex immunofluorescence panels for stromal and vascular profiling, as well as two melanoma biomarker detection in human tissues
Bastian Nicolai
Switzerland
EACR26-1723
P-599
TUMOUR BIOLOGY
Spatial multiomics analysis using over 100 biomarkers reveals immune architecture and signaling networks in diverse tumor microenvironments
Arec Manoukian
Switzerland
EACR26-1737
P-600
TUMOUR BIOLOGY
ABCC1 at the Crossroads of Metabolic Detoxification and Immune Regulation
Angelo Peschiaroli
Italy
EACR26-1743
P-601
TUMOUR BIOLOGY
TUMOR-STROMA INTERPLAY THROUGH CELLULAR AND SECRETED CEMIP IN CUTANEOUS MELANOMA
Ainhoa Alonso-Pardavila
Spain
EACR26-1755
P-602
TUMOUR BIOLOGY
Unlocking new frontiers in mouse research by exploring the whole-transcriptome in space and time with mouse embryo stages E11 – E14
Christoph Koenig
United States
EACR26-1777
P-603
TUMOUR BIOLOGY
IGFBPs as critical mediators of CAF-driven tumour progression
Ghanapriya Devi Yengkhom
India
EACR26-1791
P-604
TUMOUR BIOLOGY
CD147 defines spatially organized tumor and microenvironmental niches in posterior fossa ependymomas
Donatella Lucchetti
Italy
EACR26-1813
P-606
TUMOUR BIOLOGY
Tumor initiation from 3D spheroids establishes distinct microenvironment states in syngeneic mouse models
Agata Mlynska
Lithuania
EACR26-1859
P-607
TUMOUR BIOLOGY
Bidirectional interactions between breast cancer cells and peripheral neurons
Tessa Lohr
Norway
EACR26-1871
P-608
TUMOUR EVOLUTION AND HETEROGENEITY
Functional dissection of cancer-associated adipocytes and discovery of molecular mediators in oral cancers
Sho Miyamoto
Japan
EACR26-0009
P-634
TUMOUR EVOLUTION AND HETEROGENEITY
Spatial trajectories of TNBC tumorigenesis reveal orchestrated TME niches in time and space
Kamil Lisek
Germany
EACR26-0433
P-636
TUMOUR EVOLUTION AND HETEROGENEITY
A modular patient-derived organoid-xenograft platform reveals molecular and clinical trajectories of prostate cancer progression
Robin Dolgos
Switzerland
EACR26-0463
P-637
TUMOUR EVOLUTION AND HETEROGENEITY
Intestinal zonation constrains driver mutation selection and shapes tumour evolution in colorectal cancer
Raheleh Amirkhah
United Kingdom
EACR26-0547
P-638
TUMOUR EVOLUTION AND HETEROGENEITY
Functional interrogation of rare persistent clones reveals mechanisms of relapse in acute myeloid leukaemia (AML).
Kelsy Prest
Australia
EACR26-0555
P-639
TUMOUR EVOLUTION AND HETEROGENEITY
Deciphering spatial heterogeneity of patient-derived organoids of colorectal tumors for drug discovery
Maxim Norkin
Switzerland
EACR26-0591
P-640
TUMOUR EVOLUTION AND HETEROGENEITY
Identification of novel therapeutic targets in small cell lung cancer via multiomic profiling of rapid research autopsy samples
Karin Schelch
Austria
EACR26-0605
P-641
TUMOUR EVOLUTION AND HETEROGENEITY
Modeling relapse evolution in Colorectal Liver Metastases using patient samples and tumoroids
Soulafa Mamlouk
Germany
EACR26-0711
P-642
TUMOUR EVOLUTION AND HETEROGENEITY
Immune selection and clonal diversification drive immune evolutionary remodeling in metastatic colorectal cancer
Po-Yu Cheng
Taiwan
EACR26-0727
P-643
TUMOUR EVOLUTION AND HETEROGENEITY
Tracking neuroblastoma co-evolution in a patient-derived 3D coculture model under selective pressure
Raghad Alshadidi
Germany
EACR26-0915
P-644
TUMOUR EVOLUTION AND HETEROGENEITY
Studying the Dynamic Cell States in Pancreatic Ductal Adenocarcinoma Using In Vitro Models
Zoltán Wiener
Hungary
EACR26-1067
P-646
TUMOUR EVOLUTION AND HETEROGENEITY
Evolution of therapy resistance in neuroblastoma using patient-derived tumoroid models
Klara Ueberschär
Germany
EACR26-1125
P-647
TUMOUR EVOLUTION AND HETEROGENEITY
Increased tumor-infiltrating B-cells define neoepitopes diversity and mutational divergence of relapsed-tumors in microsatellite stable colorectal cancer
Belen Martinez-Castedo
Spain
EACR26-1367
P-648
TUMOUR EVOLUTION AND HETEROGENEITY
Quantitative and qualitative analysis of horizontal gene transfer in HT-29 colorectal carcinoma cells.
Gábor Valcz
Hungary
EACR26-1465
P-649
TUMOUR EVOLUTION AND HETEROGENEITY
Immune and epigenetic changes in breast tumors during aromatase inhibition revealed by single-cell analyses
Ilayda Altinönder
Norway
EACR26-1527
P-650
TUMOUR EVOLUTION AND HETEROGENEITY
Extended passaging drives clonal evolution and functional heterogeneity in SKOV3 ovarian cancer cell line
Egle Zymantaite
Lithuania
EACR26-1673
P-651
TUMOUR EVOLUTION AND HETEROGENEITY
An ex vivo tissue-based optogenetics model to uncover the origin and evolution of B cell lymphoma
Asli Kasapoglu
Switzerland
EACR26-1809
P-653
TUMOUR EVOLUTION AND HETEROGENEITY
3D cartography of the metabolome expands the scope for precision medicine in breast cancer
Evdoxia Karali
United Kingdom
EACR26-1901
P-654
TUMOUR IMMUNOLOGY
TRIM6‑Mediated Reduction of DCN+ CAFs Impairs CD8⁺ T‑cell Cytotoxicity and Drives Resistance to Immune Checkpoint Blockade in MSS/pMMR Colorectal Cancer
Zhangfa Song
China
EACR26-0057
P-655
TUMOUR IMMUNOLOGY
Colorectal Cancer Disrupts Circadian Rhythmicity in the Tumour Environment
George Pérez Viltre
Spain
EACR26-0161
P-657
TUMOUR IMMUNOLOGY
Effect of Gut Microbiota–Derived Short Chain Fatty Acids on Cancer Cells and Macrophage Polarization
Nefertiti El-Nikhely
Egypt
EACR26-0177
P-658
TUMOUR IMMUNOLOGY
Gut microbiota mediates the impact of oral iron therapy on colorectal cancer progression in ApcMin/+ mice
Manuela Santos
Canada
EACR26-0189
P-659
TUMOUR IMMUNOLOGY
An IL-15 fusion protein with albumin-binding domain potentiates immunotherapy in glioblastoma by modulating FGF-2/FGFR signaling and the immune microenvironment
Fei-Ting Hsu
Taiwan
EACR26-0235
P-660
TUMOUR IMMUNOLOGY
CD36 expression is associated with immunosuppressive TME features characteristic of excluded and ignored immunophenotypes in triple-negative breast cancer
Jang Bae Moon
South Korea
EACR26-0239
P-661
TUMOUR IMMUNOLOGY
ISX–TWIST1 reprograms CD47–inflammasome signaling to reshape the immune microenvironment in liver cancer
Li-Ting Wang
Taiwan
EACR26-0265
P-662
TUMOUR IMMUNOLOGY
Crosstalk between revival stem cell-like tumor cells and macrophages promotes immunosuppression in colorectal cancer.
Elia Escoffier
Switzerland
EACR26-0285
P-663
TUMOUR IMMUNOLOGY
Transcriptional and Functional Alterations of Circulating Neutrophils in Head and Neck Squamous Cell Carcinoma
Ahana Kapuge Dona Varuni Yashodha Ratnayake
Finland
EACR26-0303
P-664
TUMOUR IMMUNOLOGY
Chemo-epigenetic combination therapy empowers immune rewiring to exploit adaptive immunity against ovarian cancer
Michele De Luca#
Italy
EACR26-0383
P-665
TUMOUR IMMUNOLOGY
Role of the exocyst complex in immune escape in bladder cancer
Inna Traore
France
EACR26-0385
P-666
TUMOUR IMMUNOLOGY
Investigating the role of TREM2 in primary and metastatic brain tumors
Alessandro Matera*
Switzerland
EACR26-0449
P-668
TUMOUR IMMUNOLOGY
Integrated Spatial Multiomics workflow For Visualizing Functionally Significant Protein Interactions
Anushka Dikshit
United States
EACR26-0483
P-669
TUMOUR IMMUNOLOGY
Modelling lung tumour-microbiome crosstalk using a spatially confined host-microbe co-culture system
Sarah Spencer
Canada
EACR26-0499
P-670
TUMOUR IMMUNOLOGY
Comprehensive analysis of microbiome alterations in colorectal cancer patients
Benedek Szabó
Hungary
EACR26-0531
P-671
TUMOUR IMMUNOLOGY
Targeting macrophages to improve radiotherapy response in brain metastasis
Paola Guerrero Aruffo
Switzerland
EACR26-0533
P-672
TUMOUR IMMUNOLOGY
Development of an ex vivo model from HGSOC patient-derived ascites to study innate immune responses
Anastasia Gandini
Australia
EACR26-0551
P-673
TUMOUR IMMUNOLOGY
Deciphering the Metabolic-Immune Crosstalk Underlying ICB Resistance in MASH-HCC
Yaxian WANG
Hong Kong, China
EACR26-0575
P-674
TUMOUR IMMUNOLOGY
HLA class I and II variants shape antitumor immune response in combination
Máté Manczinger
Hungary
EACR26-0599
P-675
TUMOUR IMMUNOLOGY
Immune landscape of advanced melanoma related to response to Anti-PD1 Therapy
Fernando Becerril-Gómez
Spain
EACR26-0699
P-676
TUMOUR IMMUNOLOGY
Cathepsin S as an Immunomodulator in Lung Cancer
Sophie Tomkinson
United Kingdom
EACR26-0715
P-677
TUMOUR IMMUNOLOGY
Mechano-dependent regulation of macrophage recruitment and polarisation by Oral Squamous Cell Carcinoma cells
Bethany Bareham
United Kingdom
EACR26-0721
P-678
TUMOUR IMMUNOLOGY
CD25 as a central switch in dendritic cell activation and anti-tumor immunity
Aurora Gazzillo
Italy
EACR26-0725
P-679
TUMOUR IMMUNOLOGY
Tissue Compartmental Characterisation of γδ T Cells Differentiates Cytotoxic and Inhibitory Receptor Expression in Colon Cancer
Karla OShea
Ireland
EACR26-0775
P-680
TUMOUR IMMUNOLOGY
Decoupling tumor entry from antigen recognition reveals a distinct early phase of T cell infiltration
Camiel Gobel
Netherlands
EACR26-0779
P-681
TUMOUR IMMUNOLOGY
Employing multiomics profiling to unveil the immune landscape of a patient-relevant orthotopic lung cancer model
Lize Allonsius
Belgium
EACR26-0819
P-683
TUMOUR IMMUNOLOGY
UMG1-TRINK15: A FIRST-IN-CLASS TRISPECIFIC NK ENGAGER TARGETING MANTLE CELL LYMPHOMA
Sara Squillacioti
Italy
EACR26-0873
P-684
TUMOUR IMMUNOLOGY
Bortezomib enhances NK-driven cytotoxicity against invasive breast cancer and bone metastasis cells by restoring membrane surface expression of NKG2D ligands.
Marta Gomarasca
Italy
EACR26-0901
P-685
TUMOUR IMMUNOLOGY
Deciphering T-Cell Heterogeneity in Non-Small Cell Lung Cancer: Insights from Integrated Single-Cell and Bulk Transcriptomics
Upasna Madan
Finland
EACR26-0909
P-686
TUMOUR IMMUNOLOGY
Inhibition of IL6 trans-signalling improves anti-tumour immune responses in colorectal cancer metastasis
Michael Murrey
Australia
EACR26-0943
P-687
TUMOUR IMMUNOLOGY
TMEM33 Is a T Cell–Intrinsic Brake on CD8⁺ T Cell Anti-Tumour Immunity
Eileen Parkes
United Kingdom
EACR26-0997
P-688
TUMOUR IMMUNOLOGY
Macrophage-derived extracellular vesicles promote EP4-dependent PD-L1 upregulation in colorectal cancer- a potential translational target
Shakti Ranjan Satapathy
Sweden
EACR26-1023
P-689
TUMOUR IMMUNOLOGY
Limited inflammation impairs monocyte-derived macrophage differentiation and correlates with protumor Tim4+ resident macrophage expansion during peritoneal colorectal cancer
Natalia Álvarez-Ladrón
Spain
EACR26-1029
P-690
TUMOUR IMMUNOLOGY
Expression and Cellular Distribution of the Immune Checkpoint Inhibitor LILRB4 in Colorectal Cancer
Dávid Kis
Hungary
EACR26-1059
P-691
TUMOUR IMMUNOLOGY
Targeting Tumor Macrophage TGF-β Signaling Overcomes Immunotherapy Resistance in Hepatocellular Carcinoma
Yan Liu
China
EACR26-1105
P-692
TUMOUR IMMUNOLOGY
CD74 Deficiency Reshapes CD4+ T Cell–Dendritic Cell Crosstalk in Melanoma
Gayoung Park
Finland
EACR26-1121
P-693
TUMOUR IMMUNOLOGY
The Mutant-Targeted Catalytic RAS(ON) Inhibitor RM-055 Potentiates Antitumor Immunity and Sensitizes Immuno-refractory Syngeneic NSCLC Tumors to Anti-PD-1
Cristina Blaj
United States
EACR26-1205
P-694
TUMOUR IMMUNOLOGY
Matched tumour and tumour-draining lymphnode profiling reveals CD8+ T-cell states associated with pathological complete response after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Francesca Lucibello
France
EACR26-1215
P-695
TUMOUR IMMUNOLOGY
Microtubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast Cancer
July Aung
Finland
EACR26-1227
P-696
TUMOUR IMMUNOLOGY
The role of NRF2 (NFE2L2 gene) in tumor immunity in non-small cell lung cancer
Akshatha Gowri Kalavathi Shivakumar
Finland
EACR26-1285
P-697
TUMOUR IMMUNOLOGY
C1q+ TAMs as drivers of immunosuppression in GBM
María López Vázquez
Spain
EACR26-1341
P-698
TUMOUR IMMUNOLOGY
Tumor niche-dependent macrophage reprogramming governs response to senescence-inducing therapy in hepatocellular carcinoma
Serena Vegna
Netherlands
EACR26-1421
P-700
TUMOUR IMMUNOLOGY
Defining the breadth and dynamics of autologous T cell responses directed against tumor neoantigens in esophageal adenocarcinoma
Elisabetta Fai
Italy
EACR26-1425
P-701
TUMOUR IMMUNOLOGY
Integrated single-cell analysis reveals coordinated glycosylation and immune sensing programs in cancer metastasis
Guilherme Faria
Portugal
EACR26-1451
P-702
TUMOUR IMMUNOLOGY
Role of xCT in metastatic progression of Triple Negative Breast Cancer
Giorgia Lavina
Italy
EACR26-1473
P-704
TUMOUR IMMUNOLOGY
Properties and Applications of Chimeric Antibodies in Low-Multiplex Oncology Assays.
Silvia Sbacchi
United Kingdom
EACR26-1537
P-706
TUMOUR IMMUNOLOGY
Mass-spectrometry immunopeptidomics reveals potential cancer-specific HLA-I presented antigens in HER2 amplified cancers
Thaneswari Karpanasamy
United Kingdom
EACR26-1563
P-707
TUMOUR IMMUNOLOGY
IL-1α Signaling as a Therapeutic Lever to Sensitize KRAS-Driven NSCLC to Immunotherapy
Adele Nicolas
Austria
EACR26-1581
P-708
TUMOUR IMMUNOLOGY
Alterations in CD36+ T-, and NK cells after immune checkpoint blockade in advanced melanoma patients
Viktória Varga
Hungary
EACR26-1653
P-709
TUMOUR IMMUNOLOGY
Influence of HLA polymorphisms on age-related cancer penetrance in women with germline pathogenic BRCA1 variants
Marcell Kákonyi
Hungary
EACR26-1661
P-710
TUMOUR IMMUNOLOGY
Linking Live T Cell Function with Spatial Biology
Joseph Beechem
United States
EACR26-1731
P-711
TUMOUR IMMUNOLOGY
Lipid-associated macrophages induced by amoeboid cancer cells spatially support tumour dissemination and immunosuppression
Samantha George
United Kingdom
EACR26-1833
P-712
TUMOUR IMMUNOLOGY
Nanobody-based Tools for in-depth Research of Immuno-Oncology Targets
Philipp Becker
Germany
EACR26-1851
P-713
TUMOUR IMMUNOLOGY
YAP/TEAD activity in drug-tolerant persister cells drives immunosuppression in EGFR-mutant lung cancer
Meija Honkanen
Finland
EACR26-1877
P-714
TUMOUR IMMUNOLOGY
A20 Downregulation Enhances CD8⁺ T Cell Activity and Tumor Suppression in KRAS-Driven LUAD
Monika Homolya
Austria
EACR26-1881
P-715
TUMOUR IMMUNOLOGY
Selective PROTAC-mediated degradation of FKBP51s reprograms tumour-associated macrophages and restores anti-tumour immunity
Valeria Di Giacomo
Italy
EACR26-1885
P-716
